

March 16, 2016

NAME:

David E. Briles, Ph.D.

FIELD OF SPECIALIZATION:

Bacterial Pathogenesis and Vaccines

ADDRESS, WORK:

Department of Microbiology
658 BBRB
University of Alabama at Birmingham
Birmingham, AL 35294

ADDRESS, HOME:

760 Linwood Road
Birmingham, AL 35222

PHONE NUMBER (work/home/FAX)

(205) 934-6595 / (205) 595-9250 / (205)-934-0605

E-MAIL

dbriles@UAB.EDU

URL

<http://www.microbio.uab.edu/faculty/briles/index.html>

BIRTHDATE AND PLACE:

May 26, 1945, New York, New York

EDUCATION:

The University of Texas, B.A., 1967 (worked in the UT Genetics Foundation under Wilson Stone, Member Natl. Acad)
The Rockefeller University, Ph.D., 1973

POSITIONS HELD:

Graduate Fellow

1967-1969 (with Dr. C.A. Williams, PhD)

1969-1973 (with Dr. R.M. Krause, MD)

USPHS and USNIH Research Fellow

1973-1975 (with J. M. Davie, MD/PhD)

Research Instructor

1975-1978 (with J. M. Davie, MD/PhD)

Visiting Lecturer

Spring 1977

Assistant Professor

1978-1982

Associate Professor

1982-1985

Associate Professor

1984-1988

Professor

1985-Present

Professor

1988-Present

Professor

1988-Present

Professor

1989-2002

Adjunct Prof, of Biology 2000-Present

Adjunct Professor 2006-2012

Adjunct Prof. of Pharmacy 2009-2013

RESEARCH CENTER AFFILIATIONS:

Associate Scientist 1978-1983

The Rockefeller University, New York, New York

Laboratory of Biochemical Genetics (Edward Tatum, PhD, Lab Head)

Laboratory of Immunology and Immunochemistry (Maclyn McCarty, MD, Lab Head)

Washington Univ. School of Med., St. Louis, Missouri
Department of Pathology

Department of Microbiology and Immunology
Washington Univ. School of Med., St. Louis, Missouri

Department of Biology, Univ. Southern Illinois,
Edwardsville, Illinois

Department of Microbiology
University of Alabama at Birmingham (UAB)
Member of Tumor Institute with Max Cooper

Department of Microbiology, UAB

Department of Pediatrics, UAB

Department of Microbiology, UAB

Department of Pediatrics, UAB

Department of Genetics, UAB

Department of Comparative Medicine, UAB
(department dissolved in 2002)

Biology, Northern Illinois University, DeKalb, Illinois

Arizona State University, Tempe, Arizona

SungKyunKwan University, Suwon, Korea

Comprehensive Cancer Center, UAB

Scientist	1983-present	Comprehensive Cancer Center, UAB
Scientist	1988-present	Comprehensive Arthritis Center, UAB
Scientist	1993-present	Immunobiology Vaccine Center, UAB
Co-Director	1995-2000	Immunobiology Vaccine Center, UAB
Scientist	1995-present	Center for Aging
Senior Scholar	2000-present	Sparkman Center for International Health Education
Member	2008-present	UAB Center for Biophysical Sciences and Engineering

OTHER PROFESSIONAL ACTIVITIES

UAB:

1979-present	Immunology and Bacterial Pathogenesis for medical, dental, and graduate students.
1980-1985	Member, Animal Services Advisory Committee,
1985 - 2002	Member of the Molecular and Cellular Biology Steering Committee
1985 - 1989	Member, Cellular and Molecular Biology Steering Committee
1987 -2010	Director of the Infectious Diseases Research Training program
1985-1986	Cellular and Molecular Biology Admissions Committee,
1986-present	Member of Microbiology Graduate Steering Committee
1988-1989	Acting Director of Molecular and Cellular Biology Graduate Program
1985-1986	Member, Search Committee for Bacterial Genetics, Department of Microbiology
1986	Member, Search Committee for Chairman of Comparative Medicine Department
1978-1987	Director of Animal Care for the Cellular Immunobiology Unit of the Cancer Center
1985 -1990	Co-Director, Molecular and Cellular Biology Graduate Program
1985-1990,	Review Committee of the Cancer Center
1992-1994	Review Committee of the Cancer Center
1988-1990	Member of Vice Presidents Committee for Genetics Development
1988-present	Promotions Committee
1989-1991	Review Committee of the Comprehensive Arthritis Center
1989-2010	Director of Graduate Training in Molecular and Cellular Microbial Pathogenesis
1990-1991	Department of Microbiology Seminar Series Committee
1994-1996	Co-Chair Search Committee for Bacterial Pathogenesis
1995	Search Committee for Geographic Medicine
1995-2000	Departmental Research Development Committee
1997-1999	Search Committee for Provost
1997-2003	Search Committee for Bacterial Pathogenesis
2003-2005	Microbiology, Promotions Committee Chair
2004-2006	Immunology Search Committee
2006	Infectious Disease Search Committee
2006	Bacterial Genetics and Pathogenesis Search Committee
2007-2017	Scholarship Committee SOM
2009-2012	SBL3 Committee
2010-2012	Steering Committee for Objectives for Infectious Diseases/Global Health/Vaccines (ID-GH-V)
2011-present	Faculty Member MERIT Postdoctoral Training Program

Professional Activities Outside UAB:

1985-1988	Member Bacteriology and Mycology Study Section, NIH
1985-1989	Section Editor for bacterial immunology, Journal of Immunology,
1984-1990	Editorial Advisory Board of The Journal of Molecular and Cellular Immunology
1985-1995	Member of the Editorial Board of Microbial Pathogenesis
1987	Nominating Committee, Division B of the American Society of Microbiologists,
1985-2013	Editorial Board of Microbial Pathogenesis
1988-1994	Editorial Board of Infection and Immunity,
1988 -present	Ad Hoc Reviewer for VA, NSF, and NIH BMI and BM2 study sections
1989-1991	Reviewer for USDA Competitive Grants, Molecular Biology Program
1990	NIH AIDS & Related Research Review Group,
1991	Reviewer for Howard Hughes fellowship grants
1991-1992	ASM Foundation for Microbiology Lecturer
1992	Reviewer of CBER Bacterial Vaccines Division
1992	Bacterial Vaccines Advisor to WHO and PAHO
1994-1995	President of the Southeastern Branch of the American Society of Microbiologists

1995-1999 Member MIDRC Study section, NIH.
 1996-2000 Publications Committee American Association of Immunologists
 1999 Chair Elect of ASM Division B, Microbial Pathogenesis
 2000 – Present Fellow American Academy of Microbiology
 2001-2002 Scientific Committee ISPPD-3 (Alaska)
 2002-2008 Ad Hoc Member of NIH Diversity Predoctoral Fellowship Review
 2003-2004 Organizing Committee ISPPD-4 (Finland)
2003-2017 Editorial Board Infection and Immunity.
 2005-2006 Scientific Committee ISPPD-5 (Australia)
 2006 St. Jude External Advisory Committee, Sickle Cell Disease Center
 2006-present Scientific Advisory Board PATH Vaccine Solutions (Gates Foundation-funded pneumococcal Vaccine development)
 2007-2008 Scientific Committee ISPPD6 (Iceland)
 2008-2010 Scientific Committee ISPPD7 (Israel)
 2008-2013 Visiting Professor at SungKungKwan University and WCU Chairprofessor, National Research Foundation of Korea.
 2008-2013 Adviser for Kyounggi-Provincial Research Center, South Korea
 2008-2013 Huons Pharamceutical Co., South Korea
 2009-2013 Advisor for Jung-San Bio-engineering Co. South Korea
 2012-present International Editorial Board for Clinical Vaccine Research; Sponsored by Korean Vaccine Soc.
2012-2015 Vaccine's "Council of 100"
 2013, 2015 Ad Hoc Member of NIH Balance and Hearing Fellowship Review Panel.

MEMBERSHIPS: American Association of Immunologists
 American Society of Microbiologists
 American Society for Advancement of Science
 Infectious Diseases Society of America

HONORS: NIH, NIAID Individual Research Fellowship, 1973-1975
 NIAID Research and Career Development Award, (1982-1987)
 President of the Southeastern Branch of the American Society of Microbiologists, 1994-1995
 P. R. Edwards Award 2004 (Southeastern Branch of ASM).
 Fellow, American Academy of Microbiology ~1998 – present
 Fellow, National Academy of Inventors 2013 - present

PATENTS: 5,476,929, Structural Gene of Pneumococcal Protein, December 19, 1995
 5,679,768, Epitopic Regions of Pneumococcal Surface Protein A, October 21, 1997
 5,753,463, Structural Gene of Pneumococcal Protein, May 19, 1998
 5,871,943, Immunoassay Comprising A Truncated Pneumococcal Surface Protein A (PspA), September 8, 1998
 5,804,193, Truncated PspA Lacking a Functional Cell Membrane Anchor Region, September 19, 1998
 5,856,170, Structural Gene of Pneumococcal Protein, January 5, 1999
 8,710,840, Strain Selection of Pneumococcal Surface Proteins, September 21, 1999
 5,980,908, Epitopic Regions of Pneumococcal Surface Protein A (PspA), November 9, 1999
 6,004,802, Oral Immunization of Pneumococcal Antigens, December 21, 1999
 6,042,838, Immunogenic Compositions for Mucosal Administration of Pneumococcal Surface Protein A, March 28, 2000
 8,714,741, Pneumococcal Surface Proteins and Uses Thereof, December 31, 2002
 7,078,042, Pneumococcal Surface Protein C (PspC) Epitopic Regions and Strain Selection Thereof, and Uses Therefor", July 18, 2006

This list is out of Date as of 2013. Additional patents have been awarded.

SYMPOSIUM/SEMINAR CHAIRMAN: (Does not include Chairman of Abstract Presentations)

FASEB Conference, Session on the Evolution of Anti-Bacterial Antibody, 1983

Current Research on Bacterial Vaccines, ASM 1984.

Immune Response Humoral II, ASM, 1985.

Carbohydrate Antibodies Session of the First International Symposium on Immunoglobulin in Subclass Deficiencies, Lund, Sweden, 1985.

Surface Antigens of Bacterial Pathogens, ASM, 1986.

Section head, Block K, Microbial Immunity and Parasitology., Amer. Assoc. of Immunol., 1989 Ann. Meeting.

Adhesins - Structural Considerations, International meeting of "Microbial Adhesion and Invasion, 1990
 New Developments in Bacterial and Parasite Vaccines, ASM 1992
 Bacterial Virulence Factors, ASM 1995
 Immunology of Immune Responses, Session Organizer, ASM 1996
 Chair Division B American Society of Microbiology 1998-1999
 Session Chairman, SE ASM Meeting, 1999
 Session Chairman, SE ASM Meeting, 2000
 Session Chairman, SE ASM Meeting, 2001
 Session Chairman, International Symposium on Pneumococci and Pneumococcal Disease Finland, 2004
 Session Chairman, International Symposium on Pneumococci and Pneumococcal Disease Australia, 2006
 Session Chairman, ASM, Boston, 2008.
 Session Chairman, International Symposium on Pneumococci and Pneumococcal Disease, Iceland, 2008
 Session Co-Chair, International Symposium on Pneumococci and Pneumococcal Disease, Israel, 2010

INVITED SPEAKER (outside of UAB):

"Importance of Specificity, Idiotype and Isotype in Antibody-Mediated Anti-Pneumococcal Protection", ASM Annual Meeting, 1982.
 "Evolutionary Aspects of Antibodies to Pneumococcal Phosphocholine", FASEB Conference, 1983.
 Gordon Conference Session on Evolution of Antibacterial Antibody, 1983
 "Protective Antibodies to Noncapsular Pneumococcal Antigens", ASM Annual Meeting, 1986.
 "Studies of PspA (Pneumococcal Surface Protein A) Insertionally Inactivated Mutants" (Presented by L.S. McDaniel), Second ASM Conference on Streptococcal Genetics, 1986.
 "Growth and Killing of *Salmonella typhimurium* in Intracellular and Extracellular Compartments", ASM Annual Meeting, 1987.
 "The role of pneumococcal surface protein A in the virulence of *Streptococcus pneumoniae*" Conference of Microbial Surfaces; Determinants of Virulence and Host Responsiveness, Oakland CA 1987.
 "Pneumococcal surface protein A: Structural analysis and biological significance". (Presented by Janet Yother). Third ASM Conference on Streptococcal Genetics. 1990
 "PspA, a protection eliciting protein of the pneumococcus". Buffalo Conference on Microbial Pathogenesis, Buffalo New York 1990
 "Pneumococcal Surface Protein A: Role in Pathogenesis and Vaccine Development". Genetic Analysis of Bacterial Pathogenesis Session at the 1991 ASM Conference on Biotechnology, 1991..
 "Lessons from animal studies of salmonella pathogenesis", NIH sexually transmitted disease conference, Hamilton, Montana, 1991.
 "Pneumococcal surface protein A". WHO Scien. Meeting on New Pneumococcal Vaccines, Geneva, 1992.
 "The potential for protein vaccines against *Streptococcus pneumoniae*", Session in New Developments in Bacterial and Parasite Vaccines, ASM, Annual Meeting 1992.
 "Early Events in the Pathogenesis of Enteric Fever in Mice". NATO Salmonella Meeting, Sicily, 1992.
 "Prevention and Control of Pneumococcal Infections". ICAAC Annual Meeting, 1993.
 "Pneumococcal Proteins as Possible Alternative to a Polysaccharide-Protein Conjugate Vaccine". Annual ASM Meeting, 1994.
 "The Future of Pneumococcal Vaccines", ICAAC Annual Meeting, 1994.
 WHO/CDC Joint Workshop on Pneumococcal Vaccines, Winchester, England, 1994
 WHO/CDC/NIAID/FDA Joint Workshop on Immunologic Assays for Pneumococcal Vaccines, Atlanta, 1994.
 "Non-Capsular virulence factors of *Streptococcus pneumoniae*". ASM Division D Lecture 1995.
 "Mouse Models for Passive Protection against *Streptococcus pneumoniae*", WHO/CDC Joint workshop on Pneumococcal Vaccines, Atlanta, 1996
 "Pneumococcal Immunity", Department of Health & Human Services Antibody Workshop, Wash., DC, 1996
 "Streptococcus pneumoniae: Molecular Biology and Mechanism of Disease" Workshop, Lisbon, Portugal, 1996
 "PspA: Potential New Vaccine Candidate" Fourth Annual Work Group Meeting on Improving the Performance of Influenzae and Pneumococcal Vaccines in Adults, Institute for Advanced Studies in Immunology and Aging, Washington, DC, 1996.
 "Non-Polysaccharide Approaches for Vaccination Against Streptococcus pneumoniae", Acute Respiratory Infections in Children: Prospects for Prevention, Annecy, France, 1996.
 "Pneumococcal Vaccines", Molecular Pathogenesis of Infectious Diseases Conference sponsored by the European Science Foundation, Obernai, France, 1996.
 "Elicitation of Immunity to Pneumococci with PspA and other Experimental non-Capsular Vaccines", ASM National meeting, 1997.

- "Potential for Use of PspA as a Vaccine to Protect Against Pneumococcal Infection", National Sickle Cell Program, 1997.
- "Protein virulence factors of *Streptococcus pneumoniae* and their potential for use in vaccines to protect against colonization and infection with *S. pneumoniae*". U.S. - Japan Acute Respiratory Disease Meeting, Houston, Texas, 1998.
- "Protein Vaccines & other New Approaches". Pneumococcal Vaccines for the World, 1998 Conference. WHO Conference. Washington, DC, 1998.
- "Elicitation of Protective Antibody to PspA in Man", WHO Pneumococcal and Hib Vaccine Development and Introduction Meeting, Geneva, Switzerland, 1999.
- "Role of Mucosal Immunization for Protection Against Acquisition and Invasion of Infections with *Streptococcus pneumoniae*", Congress of Mucosal Immunology, Amsterdam, 1999.
- "Away from pneumococcal conjugates?" Overview on Vaccine Research in WHO and UNAIDS, Montreux, France, 1999.
- "Immunization of the Elderly with Conserved Surface Proteins of *Pneumococcus*". International Symposium on Immunity in the Elderly, Annecy, France, 1999.
- "Protective mucosal & systemic immunity elicited by protein antigens of pneumococci", Immunology of Infectious Diseases Symposium, Bethesda, MD, 1999
- "Use of pneumococcal virulence proteins to formulate vaccines to protect against infection", SE ASM Meeting, 1999.
- "Non polysaccharide vaccines", Otitis Media: A Preventable Disease? Meeting, Annecy, France, 2000.
- "Virulence Factors of *Streptococcus pneumoniae*", ICAAC Meeting, Toronto, Canada, 2000
- "New Vaccines for non-serotype-dependent Protection Against Pneumococcal Disease", ISAAR Meeting, Seoul, Korea 2001
- "Protein Vaccines for Pneumococci", NIH of Korea, 2001
- "Protein Pneumococcal Vaccine for Children", Gates Foundation for Children's Vaccines 2001
- "Protection of the elderly from pneumococcal pneumonia with a protein based vaccine?" 2002 International Conference on Immunology and Aging, Washington D.C. 2002
- "Potential for Protein Vaccines to Protect the Elderly from Infections with *Streptococcus pneumoniae*." Immunobiology and Aging, Washington, D.C. 2002.
- "Protein Vaccines for Protection Against Pneumococci" ISPPD, Anchorage, Alaska, 2002.
- "Protein Vaccines for Protection Against Pneumococci" JCS, Kobe, Japan, 2002.
- "Subtle means by which the pneumococcus colonizes and invades" Conference Louis Pasteur. Paris, 2002
- "Protein vaccines for pneumococcal disease", Pneumococcal Vaccine Workshop. Key Lago, FL 2003
- "Pneumococcal Proteins that may constitute the Next Generation Vaccine for Pneumococcal Disease", 5th International symposium on Tonsils and Mucosal Barriers of the Upper Airways, Wakayama, Japan, 2003
- "Pneumococcal Surface Protein Vaccine Candidates", 8th International Symposium on Recent Advances in Otitis Media, Ft. Lauderdale, FL, 2003.
- "Effects of PspA, NanA, and Antibodies to PspA on Virulence of *Streptococcus pneumoniae*" Pneumococcal Vaccine Workshop. Key Lago, FL 2004
- "Why Should we have a Protein Antigen", Pneumococcal Disease: vaccine Strategies, Washington, DC, 2003
- "Effects of PspA, NanA, and Antibodies to PspA on Virulence of *Streptococcus pneumoniae*" Pneumococcal Vaccine Workshop. Key Lago, FL 2005
- "Animal Models and Surrogate Assays for Testing Candidate Pneumococcal Vaccines", PATH, Washington DC 2005
- "Surface Proteins of *Streptococcus pneumoniae*: Their Roles in Virulence and Potential as Vaccines" 6th Pneumococcal Disease Society Meeting, Tokyo, Japan, 2005
- Invited participant (presentation by Roy C. Curtis III), Grand Challenges in Global Health Meeting, Gates Foundation, Seattle, WA, 2005
- "PspA Inhibits the Antibacterial Effects of Apolactoferrin on *Streptococcus pneumoniae*". VII International Conference on Lactoferrin, Honolulu, Hawaii 2006
- "Pneumococcal Species-Specific Protein Vaccines: Prospects. International Symposium on Pneumococci and Pneumococcal Disease 5, Alice Springs, Australia 2006.
- "New Antigenic Targets for Pneumococcal Vaccines", Symposium on Immunobiologicals and Human Health, Bio-Manguinhos, Rio De Janeiro, Brazil 2006
- "Surface Proteins of *Streptococcus pneumoniae*: Their Roles in Virulence and Potential as Vaccines". Euroconference on Infection and Lung Diseases, Institut Pasteur, Paris France 2006
- "Protein Vaccine against Pneumococci: A Path to the Future" ASM Foundation Speaker, American Society of Microbiology, Hawaii Branch, Annual Meeting 2006.

- "Immunization with mixtures of pneumococcal virulence molecules can prevent pneumococcal disease in mice", Microbiology Society of Korea, Pyeong Chang, Korea, 2007
- "Protein Vaccines for Pneumococcal Disease, Pharmaceutical Society of Korea, Kwang-Joo, Korea, 2007
- "The interaction of *Streptococcus pneumoniae*, PspA, and lactoferrin", ASM foundation Speaker, American Society of Microbiology, Indiana Branch, Annual Meeting, 2007.
- "Pneumococcal protein vaccines", REBVAC Workshop, Siena, Italy 2007.
- "The Ying and Yang of Colonization and Infection With *Streptococcus pneumoniae*. ASM Annual Meeting, Boston 2008.
- "PspA plays a major role in the protection of pneumococci from lactoferrin" International Symposium on Pneumococci and Pneumococcal Disease 6. Reykjavik, Iceland. 2008.
- "Effect of PspA and PspC on complement deposition and Immune Adherence", The Microbiology Society of Korea, 2009.
- "Animal Models to Evaluate Protein Vaccine Antigens". PATH/NIAD Pneumococcal Meeting, Washington DC, 2010.
- "Elicitation of Mucosal Immunity by Proteins of *Streptococcus pneumoniae*", Second Microbial Pathogenesis Immunity Symposium, Suwon, Korea 2010.
- "Selection of *Streptococcus pneumoniae* capsular types by the pneumococcal conjugate vaccine and by cystic fibrosis". 7th International symposium of tonsils and mucosal barriers of upper airways, Asahikawa, Japan, 2010.
- "Elicitation of Immunity against colonization by antigens of *Streptococcus pneumoniae*". 7th International symposium of tonsils and mucosal barriers of upper airways, Asahikawa, Japan. 2010.
- "Virulence mechanisms of a pneumococcal surface protein. WCU Symposium Suwon South Korea 2011.
- "Virulence mechanisms of Pneumococcal surface protein A (PspA), Korean Society of Microbiology, DaeChun, South Korea. 2011
- Mechanism of Inactivation of Complement C3 by PspA. WCU Symposium Suwon South Korea 2012
- PspA's inhibits classical pathway complement deposition on the pneumococcal surface by competing with surface binding of CRP (short talk), ISPPD8 Iguacu Falls, Brazil, 2012
- Streptococcus pneumoniae*, Captain of the Men of Death, Chung-Ang University School of Pharmacy, Biomedical Sciences Symposium, Seoul, South Korea, 2012
- PspA's role in protection against complement. Microbiology Society of Korea, Seoul South Korea 2012
- A role for protein antigens in pneumococcal vaccines and the Expression of PspA families after a decade of conjugate vaccine use. In The 7th Ewha Vaccine Symposium, Seoul Korea. 2012
- "DogmaHidesBeauty", Infant Health Workshop, Key Largo FL, 2013
- "Non-Capsular Vaccines for *Streptococcus pneumoniae*", The Fifth Microbial Pathogenesis Symposium, Suwon, S. Korea 2013
- "*Streptococcus pneumoniae* non-capsular vaccines", Korean Society of Microbiology, Chuncheon Korea, 2013
- "Non capsular vaccines for pneumococci" and "Animal models to evaluate protein vaccine antigens", Tsinghua University School of Medicine, Beijing China 2013
- "Non-capsular vaccine for *Streptococcus pneumoniae*". Liquidia, Research Triangle Park NC. July 2013.
- Putative Pneumococcal Proteins: their mechanisms of action, 7th Extraordinary International Symposium on Recent advances in Otitis Media, Stockholm, Sweden 2013
- Non-capsular vaccines for *Streptococcus pneumoniae*, why and how? Univ, Texas School of Public Health, Houston Texas. March, 2014.
- "Memorial For Patti Hall". Pneumo Symposium, Birmingham, Alabama, April 28, 2014
- "PspA a vaccine component". University of Tokyo, September 2014.
- "New Perspectives on Protein Vaccines with a focus on PspA". Butantan Instituto, Sao Paulo, Brazil April 2015
- "Potential and Problems with Protein Vaccines for Pneumococci" and "Surrogate Assays for Antibody to PspA: How and Why". Albany Medical College, Albany New York, May 2015.

INVITED UNIVERSITY, FEDERAL LABORATORY, and CORPORATE LECTURES, since 1981

- National Institutes of Health, 1981, 1983
- University of Texas Health Science Center, Dallas, TX, 1983
- Rush Medical Center, Chicago, IL, 1983
- University of Missouri, Columbia, MO, 1984
- Emory University, Atlanta, GA, 1985
- Washington University, St. Louis, MO, 1985
- Gothenberg, Sweden, 1985
- University of Michigan, Ann Arbor, MI, 1986

Northwestern Medical School, Chicago, IL, 1986
State University of New York at Stony Brook, 1987
University of Oklahoma, Oklahoma City, 1987
Rush Medical College, Chicago, IL, 1988.
Baylor College of Medicine, Houston, TX, 1989
Washington University, St. Louis, MO, 1989
Connaught Laboratories, Swiftwater PN, 1989
University of Texas Southwestern, Dallas, TX, 1989
University of Tennessee, Memphis, TN, 1990
State University of New York at Buffalo, 1990
Merck, Sharp and Dohme, Philadelphia, PA, 1990
Wake Forrest Univ. Med. Center, Winston-Salem NC, 1991
Case Western Reserve Univ, Cleveland, OH, 1991
Connaught Laboratories, Swiftwater PA, 1991
Medimmune Inc., Fredrick, MD, 1991
CEBR (FDA), Bethesda MD, 1992
University of Oklahoma, Oklahoma City, OK , 1992
Medimmune, Inc., Fredrick, MD, 1992
Genentech, San Francisco, CA, 1992
Alabama State University, Montgomery, AL 1992
Washington University St. Louis, MO 1993
Centers for Disease Control, Atlanta, GA 1993
Centers for Disease Control, Atlanta, GA 1993
Uniformed Services Medical School, Bethesda, MD 1993
University of Iowa, Iowa City, Iowa, 1994
National Academy of Sciences, Institute of Medicine, Washington, DC 1994
University of Lund, Lund, Sweden, 1994.
Duke Medical School, Durham, NC, 1994
Fogerty Institute, Toxic Streptococcal Disease 1995
Fogerty Institute, Emerging Infections 1995
University of Helsinki, Finland 1995
University of Lund, Sweden 1995
University of Mississippi, Jackson, 1996
Medical School of Ohio, Toledo, Ohio, 1998
Auburn Univ. Auburn AL, 1998
University of Iowa, Iowa City, Iowa, 1998
Alabama State University, 1999
Eli Lilly Corporation, 1999
Vaccine Development for Elderly CDC 2000
Medical School, Reykjavik, Iceland, 2000
Northern Illinois, Univ. 2001
Vaccine Development, Aventis, Barcelona Spain 2001
Albany Medical College, Albany, NY, 2002
University of Texas Medical Center, Galveston, TX, 2002
University of Wakayama, Japan 2002
Syntonix, Boston, MA, 2002
Aventis, Toronto, Canada, 2002.
University of Texas SouthWestern, Dallas, 2003
University of Mississippi Medical Center, Jackson, MS. , 2003
University of Cincinnati, Cincinnati, Ohio, 2003
University of Pennsylvania, Philadelphia, PA 2004
University of Tennessee at Memphis, 2004
University of Oklahoma, 2005
Sanofi Pasteur, Toronto, Canada 2005
Arizona State University, 2005
University of Texas at Brownsville, 2005
Intercell, Vienna, Austria, 2006
Westmead Hospital, Sydney, Australia 2006

University of Melbourne, Australia 2006
 University of Adelaide, Australia 2006
 University of Queensland, Brisbane, Australia, 2006
 Butantan Institute Sao Paulo, Brazil, 2006
 Biodesign Institute Arizona State University 2006
 International Vaccine Institute, Seoul, Korea, 2007
 Korean National Institute of Health, Seoul, Korea, 2007
 Ewha Medical Research Institute, Ewha University, Seoul, Korea, 2007
 Sanofi Pasteur, Toronto, Canada, 2007
 University of Minnesota Otitis Media Study Group 2007
 University of Minnesota Pediatric Grand Rounds 2007
 University of Texas Health Science Center, San Antonio, Seminar 2008.
 Wake Forest University, 2009
 Mississippi State, 2009
 University of Texas Health Science Center, Brownsville, 2009.
 University of Massachusetts Medical School, Worcester, MA, 2010.
 University of Texas Health Science Center, Brownsville, 2010.
 Chungnam National University, Daejeon South Korea. 2010.
 Catholic University, Daegu, Korea. 2010.
 International Vaccine Institute. Seoul, Korea. 2010
 Instituto Butantan, Sao Paulo, Brazil 2010
 University of Minnesota School of Medicine, Minneapolis, MN 2010
 Alabama State University, 2011
 Korean KFDA 2011
 ChonnamNationalUniversity, Seoul ,South Korea 2011
 Instituto Butantan, Sao Paulo, Brazil 2012
 CanSino Vaccines, TinJin, China 2012
 Seoul National University School of Dentistry, Seoul South Korea, 2012
 Samsung Medical Center, Division of Infectious Diseases, Seoul South Korea, 2013
 Cell Trion Inc. Incheon S. Korea 2013
 Samsung Medical Center, Presentation to Medical Students & Graduate Students, Seoul S. Korea, 2013
 Tsinghua University School of Medicine, Center for Infectious Diseases Research, Beijing, China, 2013
 Liquidia, Incorporated, Research Triangle Park NC, 2013
 School of Public Health, Houston, Texas 2014
 University of Tokyo 2014
 Instituto Butantan, Sao Paulo Brazil 2015
 Albany Medical College, Albany New York, 2015

TEACHING EXPERIENCE -- COURSES TAUGHT (not including individual lectures in other courses) (All courses at UAB unless otherwise indicated):

Immunology for Undergraduates at Southern Illinois University, Edwardsville, 1977
 Graduate Immunogenetics, Co-director, 1979, 1985
 Director of Immunology Journal Club, 1979-1985
 Coordinator for Laboratory Rotations 1980-1984
 Graduate Statistics for Microbiology and Immunology, Director, 1987
 Laboratory Rotation Course for CMB students, Director, 1990-1993.
 Graduate Course in Bacterial Pathogenesis, Director, 1992
 Graduate Course in Bacterial Pathogenesis, Director, 1996
 Graduate Course in Bacterial Pathogenesis, Director, 1998
 Graduate Course in Bacterial Pathogenesis, Director, 2000
 Bacteriology Section, MS II Microbiology, Director, 2000
 Bacteriology Section, MS II Microbiology, Director, 2001
 Bacteriology Section, MS II Microbiology, Director, 2002
 Bacteriology Section, MS II Microbiology, Director, 2003
 Graduate Course in Bacterial Pathogenesis, Director, 2003
 Bacteriology Section, MS II Microbiology, Director, 2004
 Bacteriology Section, MS II, Microbiology, Director, 2005
 Graduate Course in Bacterial Pathogenesis, Director, 2005

Graduate Course in Bacterial Pathogenesis, Director, 2006
Bacteriology Section, MS II, Microbiology, Director, 2006
Brief Graduate Course in Bacterial Pathogenesis, Butantan Instituto, Sao Paulo, Brazil 2006
Graduate Course in Bacterial Pathogenesis, Director, 2007
Bacteriology Section, MS II, Microbiology, Director, 2007
Graduate Course in Bacterial Pathogenesis, Director, 2008
Graduate Course in Bacterial Pathogenesis, Director, 2009
Advanced Graduate Course in Bacterial Pathogenesis, Director, 2009
Graduate Bacterial Pathogenesis, Sung Kyung Kwan University, Suwon, Korea 2009
Graduate Course in Bacterial Pathogenesis, Director 2010
Advanced Graduate Course in Bacterial Pathogenesis (UAB), 2010
Advanced Graduate Course in Gram Positive Bacteria, SKKU, Korea, 2010
Bacterial Pathogenesis Course, Butantan Instituto, Sao Paulo 2010
Graduate Bacterial Pathogenesis, SKKU, Suwon, Korea, 2010
Graduate Course in Bacterial Pathogenesis (UAB), Director 2011
Graduate Bacterial Pathogenesis, SKKU, Suwon, Korea, 2011
Advanced Course in Pulmonary Disease, Lecture on Pneumococci (UAB) 2011
Graduate Course in Bacterial Pathogenesis (UAB), Director 2012
Graduate Bacterial Pathogenesis, SKKU, Suwon, Korea, 2012
Advanced Course in Pulmonary Disease, Lecture on Pneumococci (UAB) 2012
Graduate Course in Bacterial Pathogenesis (UAB), Director 2013
Graduate Bacterial Pathogenesis, SKKU, Suwon, Korea, 2013
Advanced Course in Pulmonary Disease, Lecture on Pneumococci (UAB) 2013
Graduate Course in Bacterial Pathogenesis (UAB), Director 2014
Advanced Course in Pulmonary Disease, Lecture on Pneumococci (UAB) 2014
Graduate Course in Bacterial Pathogenesis (UAB), Director 2015

CURRENT ANNUAL TEACHING RESPONSIBILITIES:

6 hours of Microbial Pathogenesis in the Graduate Immunology Course
2 hours of Microbial pathogenesis in Fundamentals Dental/Optometry Microbiology
2 hours of Lecture Medical Fundamentals II.

MEDICAL AND DENTAL COURSE LECTURES FROM 1995 TO PRESENT:

Genetics of Host Parasite Interaction, CMB V, 2 hr, 1992
Enterics I and II Lecture, Dental Students, 1992
Enterics I and II Lecture, Dental Students, 1993
Genetics of Host Parasite Interaction, CMB V, 2 hr, 1993
Bacterial Enteric Lectures, Medical Students, 2 hr, 1993
Genetics of Host Parasite Interaction, Cellular and Molecular Biology V, 2 hr, 1994
Enterics I and II Lecture, Dental Students, 1994
Immunity to Infection, Including Aids, Vaccines, Medical Microbiology, 1 hr, 1994
Immune Response Genes, Immunogenetics, 2hr, 1995
Genetic Control of Infection, Medical Microbiology, 2hr, 1995
Microbial Pathogenesis, Cellular and Molecular Biology V (Immunology) 2hr, 1995
Immunogenetics, Dental Students, 2 hr., 1995
Microbial Pathogenesis, Dental Students, 2 hr, 1997
Molecular Epidemiology Course lecture, 1 hr, 1997
Microbial Pathogenesis, Dental Students, 1 hr, 1998
Microbial Pathogenesis, Cellular and Molecular Biology V (Immunology) 2hr, 1998
Animal Resource Program Lecture, 2 hr., 1998
Microbial Pathogenesis, Cellular and Molecular Biology V (Immunology), 2 hr, 1999
School of Public Health Lecture, 2 hr, 1999
Animal Resource Program Lecture, 2 hr, 1999
Microbial Pathogenesis, Cellular and Molecular Biology V (Immunology), 2 hr, 2000
Immunogenetics, Dental Students, 2 hour, 2000
Emerging Infectious Diseases Lecture, 2 hours, 2001
Microbial Pathogenesis, Cellular and Molecular Biology V (Immunology), 2 hr, 2001
Microbial Pathogenesis, Dental Students, 2 hr, 2002

Medical Microbiology , Bacteriology, Medical Students, 2 hours, 2002
 Microbial Pathogenesis, Cellular and Molecular Biology V (Immunology), 2 hr, 2002
 Microbial Pathogenesis, Dental Students, 2 hr, 2003
 Medical Microbiology, Bacteriology, Medical Students, 2 hours, 2003
 Medical Microbiology, Bacteriology, Medical Students, 2 hours, 2004
 Microbial Pathogenesis, Dental Students, 2 hours, 2004
 Medical Microbiology, Bacteriology, Medical Students, 2 hours, 2005
 Microbial Pathogenesis, Dental Students, 2 hours, 2005
 Microbial Pathogenesis, Cellular and Molecular Biology V (Immunology), course master 2003-2006
 Medical Microbiology, Bacteriology, Medical Students, 2 hours, 2006
 Microbial Pathogenesis, Dental Students, 2 hours, 2006
 Microbial Pathogenesis, Dental Students, 1 hours, 2007
 Medical Microbiology, Bacteriology, Medical Students, 2 hours, 2007
 Medical Fundamentals II, Infectious Diseases 2 hours 2007.
 Microbial Pathogenesis, Dental Students, 2 hours, 2008
 Medical Fundamentals II, Infectious Diseases 2 hours 2008.
 Microbial Pathogenesis, Dental Students, 1 hours, 2009
 Medical Fundamentals II, Infectious Diseases 2 hours 2009.
 Graduate Immunology, Microbial Pathogenesis, 2 hours, 2009
 Medical Fundamentals II, Intro to Infect. Dis, 1 hour, 2010
 Medical Fundamentals II, Microbial Pathogenesis, 1 hr, 2010
 Dental Fundamentals I, Bacterial Pathogenesis, 2 hr, 2010
 Medical Fundamentals II, Intro to Infect. Dis, 1 hour, 2011
 Medical Fundamentals II, Microbial Pathogenesis, 1 hr, 2011
 Dental Fundamentals I, Bacterial Pathogenesis, 2 hr, 2011
 Medical Fundamentals II, Intro to Infect. Dis, 1 hour, 2012
 Medical Fundamentals II, Microbial Pathogenesis, 1 hr, 2012
 Dental Fundamentals I, Bacterial Pathogenesis, 2 hr, 2012
 UAB Medical Student Pre-Matriculation Program 2 hr, 2012
 Dental Fundamentals I Microbial Pathogenesis, 2 hr, 2013
 Medical Fundamentals II, Intro to Infect. Dis, 1 hour, 2013
 Medical Fundamentals II, Microbial Pathogenesis, 1 hr, 2013
 Medical Fundamentals II, Microbial Pathogenesis, 1 hr, 2014
 Dental Fundamentals II, Microbial Pathogenesis, 1 hr, 2014
 Medical Fundamentals II, Microbial Pathogenesis, 1 hr 2015
 Dental Fundamentals II, Microbial Pathogenesis, 1 hr 2015

INVITED SPEAKER, UAB, since 1993.

"A Potential Protein Vaccine to Protect Against Pneumococcal Infection in Children", Infectious Disease Seminar, May, 1993.
 "A Marker for Death", Pulmonary Research Forum, March, 1993.
 "Mucosal Immunity and Pneumonia", Pulmonary Research Forum, May 1995.
 Infectious Disease Conference Speaker, 1996
 Immunology Seminar Speaker, 1996
 Pulmonary Research Forum Speaker, 1997
 Immunology Seminar Speaker, 1997
 Animal Resource Program Seminar Series Speaker, 1997
 Aging Center Seminar Series Speaker, 1997
 Microbiology Retreat, Featured Speaker, 1997
 Gene Therapy Seminar Series, 1997
 Immunology Seminar Speaker, 1998
 Cancer Center Retreat, 1999
 Immunology Seminar Speaker, 1999
 Biology of Aging Retreat, 1999
 Immunology Seminar Speaker, 2000
 Microbiology Departmental Seminar 2002
 Sparkman Center, 2002

Mucosal Immunology Seminar Speaker, 2003
 Immunology Seminar Speaker, 2003
 Mucosal Immunology Seminar Speaker, 2004
 Immunology Seminar Speaker, 2004
 Mucosal Immunology Seminar Speaker, 2005
 Immunology Seminar Speaker, 2005
 Mucosal Immunology Seminar Speaker, 2006
 Immunology Seminar Speaker, 2006
 Immunology Seminar Speaker, 2007
 Microbiology Seminar Speaker, 2008
 Program In Immunology Series, 2010
 Microbiology Retreat Speaker, San Destin, FL 2012
 Microbiology Faculty Research Retreat 2015

Recent Findings Put in the Public Domain.

pUAB201 (expression plasmid for expression of alpha helical domain of pneumococcal surface protein A (PspA) of strain D39 (Family 1)) EESPVASQSKEADYDAAKKDAKNAKKAVERDAQKALDDAKAAQKKYDEDQKKTEE
 KAALEKAASEMDKAVAAVQQAYLAYQQATDKAAKDAADKMIDEAKKREEEAKTKFNTVRAMVVPEPEQLAETKKKSEEAQK
 KAPELTKKLEEAkakLEEAkakKATEAKQKVDAAEEVAPQAKIAELENQVHRLEQELKEIDEESEDYAKEGFRAPLQSKLDAKK
 AKLSKLEELSDKIDELDAEIAKLEDQLKAAEENNNVEDYFKEGLEKTIAAKKAELEKTEADLKKAVNEPEKPAPAPETPAPE --
 the identical amino acid sequence as UAB055
 pUAB202 (expression plasmid for expression of alpha helical domain of pneumococcal surface protein A (PspA) of strain V24 (Family 2)): EESPVASQSKEADYDAAVKKSEAAKKHYEEAKKKAEDAQKKYDEDQKKTEAKA
 EKERKASEKIAEATKEVQQAYLAYLQASNESQRKEADKKIKEATQRKDEAEAAAFATIRTTIVVPEPELAETKKKAAEEAKAEEK
 VAKRKYDYATLKLALAKKEVEAKELEIEKLQYEISTLEQEVATAQHQVDNLKLLAGADPDDGTEVIEAKLKKGEAELNAKQAE
 LAKKQTELEKLLDSDPEGKTQDELDEKAEAEALDKKADELQNKVADLEKEISNLEILLGGADPEDDTAALQNKLAAKKAELAK
 KQTELEKLLDSDPEGKTQDELDEKAEAEALDKKADELQNKVADLEKEISNLEILLGGADSEDDTAALQNKLATKKAELEKTQK
 ELDAALNELGPDGDEEETPP -- the identical amino acid sequence as UAB099

BIBLIOGRAPHY

PRIMARY (REVIEWED) PUBLICATIONS

- Briles DE, RM Krause: **Mouse antibodies to Group A streptococcal carbohydrate: Use of idiotype to detect inbred strain specificity and to monitor spleen cell transfer in syngeneic mice.** *J. Immunol.* 109:1311-1120, 1972.
- Briles DE: **Studies on the inheritance of idiotype markers of mouse antibodies to streptococcal Group A carbohydrate and on other genetic factors which influence the immune response.** Thesis, The Rockefeller University, 1973.
- Briles DE, RM Krause: **Mouse strain specific idiotype and interstrain idiotypic cross-reactions.** *J. Immunol.* 113:522-530, 1974.
- Schroer KR, DE Briles, JAVan Boxel, JM Davie: **Idiotypic uniformity of cell surface immunoglobulin in chronic lymphocytic leukemia: Evidence for monoclonal proliferation.** *J. Exp. Med.* 140:1416-1420, 1974.
- Briles DE, JM Davie: **Clonal dominance. I. Restricted nature of the IgM antibody response to Group A streptococcal carbohydrate in mice.** *J. Exp. Med.* 141:1291-1307, 1975.
- Briles DE, JM Davie: **Detection of isoelectric focused antibody by autoradiography and hemolysis of antigen-coated erythrocytes. A comparison of methods.** *J. Immunol. Methods*, 8:363-372, 1975.
- Hansburg D, DE Briles, JM Davie: **Analysis of the diversity of murine antibodies to dextran B1355. I. Generation of a large pauci-clonal response by a bacterial vaccine.** *J. Immunol.* 117:569-575, 1976.
- Briles DE, RM Krause, JM Davie: **Immune response deficiency of BSVS mice. I. Identification of Ir gene differences between A/J and BSVS mice in the anti-streptococcal Group A carbohydrate response.** *Immunogenetics.* 4:381-392, 1977.
- Perlmutter RM, DE Briles, JM Davie: **Complete sharing of light chain spectrotypes by murine IgM and IgM**

- anti-streptococcal antibodies.** *J. Immunol.* 118:2161-2166, 1977.
- Hansburg D, DE Briles, JM Davie: **Analysis of the diversity of murine antibodies to dextran B1355. II. Demonstration of multiple idiotypes with variable expression in several strains.** *J. Immunol.* 119:1406-1412, 1977.
- Perlmutter RM, DE Briles, JM Greve, JM Davie. **Light chain diversity of murine antistrep- antibodies: IgC_H-linked effects on L chain expression.** *J. Immunol.* 121:149-158, 1978.
- Hansburg D, RM Perlmutter, DE Briles, JM Davie: **Analysis of the diversity of murine antibodies to dextran B1355. III. Idiotypic and spectrotypic correlations.** *Eur. J. Immunol.* 8:352-359, 1978.
- Perlmutter RM, D Hansburg, DE Briles, RA Nicolotti, J M Davie: **Subclass restriction of murine anti-carbohydrate antibodies.** *J. Immunol.* 121:566-572, 1978.
- Briles DE, RM Perlmutter, D Hansburg, JR Little, J M Davie: **Immune response deficiency of BSVS mice. II. Generalized deficiency to thymus-dependent antigens.** *Eur. J. Immunol.* 9:255-261, 1979.
- Nicolotti RA, DE Briles, JA Schroer, JM Davie: **Isoelectric focusing on immunoglobulins: Improved methodology.** *J. Immunol. Methods.* 33:101-115, 1980.
- Briles DE, JM Davie: **Clonal nature of the immune response II. The effect of immunization on clonal commitment.** *J. Exp. Med.* 152:151-160, 1980.
- Briles DE, RJ Carroll : **A simple method for estimating the probable numbers of different antibodies by examining the repeat frequencies of sequences or isoelectric focusing patterns.** *Mol. Immunol.* 18:29-38, 1981.
- Briles DE, M Nahm , K Schroer , J Davie, P Baker , JF Kearney, R Barletta : **Anti-phosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 S. pneumoniae.** *J. Exp. Med.* 153:694-705, 1981.
- Briles DE, J Lehmeyer, C Forman: **Phagocytosis and killing of Salmonella typhimurium by peritoneal exudate cells.** *Infect. Immun.* 33:380-388, 1981.
- Briles DE, WH Benjamin Jr, CA Williams, JM Davie: **A genetic locus responsible for salmonella susceptibility in BSVS mice is not responsible for the limited T-dependent immune responsiveness of BSVS mice.** *J. Immunol.* 127:906-911, 1981.
- Briles DE, JL Claflin, K Schroer, C Forman: **Mouse IgG₃ antibodies are highly protective against infection with Streptococcus pneumoniae.** *Nature.* 294:88-90, 1981.
- Yother J, C Forman, B Gray, DE Briles: **Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody.** *Infect. Immun.* 36:184-188, 1982.
- Marion TN, AR Lawton III, JF Kearney, DE Briles: **Anti-DNA autoantibodies in (NZBxNZW) F₁ mice are clonally heterogeneous but the majority shared a common idotype.** *J. Immunol.* 128:668-674, 1982.
- Briles DE, M Nahm, TN Marion, RM Perlmutter, JM Davie: **Streptococcal group-A carbohydrate has properties of both a thymus independent (TI-2) and a thymus-dependent antigen.** *J. Immunol.* 128:2032-2035, 1982.
- Yother J, JE Volanakis, DE Briles: **Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice.** *J. Immunol.* 2374-2376, 1982.
- Lejeune JM, DE Briles, AR Lawton, JF Kearney: **Estimate of light chain repertoire size of fetal and adult BALB/cJ and CBA/J mice.** *J. Immunol.* 129:673-677, 1982.
- Briles DE, C Forman, S Hudak, JL Claflin: **Anti-PC antibodies of the T15 idotype are optimally protective against Streptococcus pneumoniae.** *J. Exp. Med.* 156:1177-1185, 1982.
- Basta P, H Kubagawa, JF Kearney, DE Briles: **Ten percent of normal B cells share a V_H determinant(s) (J606-GAC) with a distinct subset of murine V_H III plasmacytomas.** *J. Immunol.* 130:2423-2428, 1983.
- Wallick S, JL Claflin, DE Briles: **Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugate.** *J. Immunol.* 130:2871-2875, 1983.
- Gray BM, HC Dillon, DE Briles: **Epidemiological studies of Streptococcus pneumoniae in infants:**

- Development of antibody to phosphocholine.** *J. Clin. Microbiol.* 18:1102-1107, 1983.
- Basta P, DE Briles : **The mouse heavy chain variable region marker, J606-GAC, is not restricted to particular B cell isotypes or subsets.** *J. Immunol.* 132:783-786, 1984.
- McDaniel LS, G Scott , JF Kearney, DE Briles: **Monoclonal antibodies against protease sensitive pneumococcal antigens can protect mice from fatal infection with *Streptococcal pneumoniae*.** *J. Exp. Med.* 160:386-397, 1984.
- Colwell D, SM Michalek, DE Briles, E Jirillo, JR McGhee : **Monoclonal antibodies to Salmonella lipopolysaccharide: Anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent *Salmonella typhimurium*.** *J. Immunol.* 153:950-957, 1984.
- Conley ME, DE Briles: **Lack of IgA subclass restriction in antibody response to phosphorycholine, B-lactoglobulin and tetanus toxoid.** *J. Immunology.* 53:419-426, 1984.
- Briles DE, C Forman, S Hudak, JL Claflin: **The effects of subclass on the ability of IgG anti-phosphocholine antibodies to protect mice from fatal infection with *Streptococcal pneumoniae*.** *J. Mol. Cell. Immunol.* 1:305-309, 1984.
- McDaniel LS, WH Benjamin Jr, C Forman, DE Briles: **Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia.** *J. Immunol.* 133:3308-3312, 1984.
- Briles DE, C Forman , S Hudak, JL Claflin: **The effects of idiotypic on the ability of IgG₁ anti-phosphocholine antibodies to protect mice from fatal infection with *Streptococcus pneumoniae*.** *Eur. J. Immunol.* 14:1027-1030, 1984.
- Hagberg L, DE Briles, C Svanborg-Eden: **Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice that effect susceptibility to gram negative infections.** *J. Immunol.* 134:4118-4122, 1985.
- Benjamin WH Jr, CL Turnbough Jr, BS Posey, DE Briles: **The ability of *Salmonella typhimurium* to produce the siderophore enterobactin is not a virulence factor in mouse typhoid.** *Infect. Immun.* 50:392-397, 1985.
- Kearney JF, MTM McCarthy, R Stohrer, WH Benjamin Jr, DE Briles: **Induction of germ-line anti-a1-3 dextran antibody responses in mice by members of the enterobacteriaceae family.** *J. Immunol.* 135:3468-3472, 1985.
- Briles DE, WH Benjamin Jr, B Posey, SM Michalek, JR McGhee: **Independence of macrophage activation and the expression of alleles of the Ity (Immunity to typhimurium) locus.** *Microbial Pathogenesis* 1:33-41, 1986.
- Benjamin WH Jr, CL Turnbough Jr, BS Posey, DE Briles: ***Salmonella typhimurium* virulence genes necessary to exploit the Ity^{s/s} genotype of the mouse.** *Infect. Immunol.* 51:872-878, 1986.
- Benjamin WH Jr, CL Turnbough Jr, JD Goguen, BS Posey, DE Briles: **Genetic mapping of novel virulence determinants of *Salmonella typhimurium* to the region between *trpD* and *supD*.** *Microbial Pathogenesis* 1:115-124, 1986.
- Benjamin WH Jr, BS Posey, D Briles: **Effects of in vitro growth phase on the pathogenesis of *Salmonella typhimurium* in mice.** *J. Gen. Microbiol* 132:1283-1295, 1986.
- Musher DM, AJ Chapman, A Goree, S Jonsson, DE Briles, RE Baughn: **Natural and vaccine-related immunity to *Streptococcus pneumoniae*.** *J. Infect. Dis.* 154:245-256, 1986.
- Nahm MH, RM Blaese, MJ Crain, DE Briles: **Patients with Wiskott-Aldrich syndrome have normal IgG2 levels.** *J. Immunol.* 137:3484-3487, 1986.
- McDaniel LS, G Scott, K Widenhofer, J Carroll, DE Briles: **Analysis of a surface protein of *Streptococcus pneumoniae* recognized by protective monoclonal antibodies.** *Microbial Pathogenesis.* 1:519-531, 1986.
- Yother J, LS McDaniel, DE Briles: **Transformation of encapsulated *Streptococcus pneumoniae*.** *J. Bacteriol.* 168:1463-1465, 1986.
- McDaniel LS, J Yother, L Vijayakumar, M McGarry, WR Guild, DE Briles: **Use of insertional inactivation to**

- facilitate studies of biological properties of pneumococcal surface protein A (PspA). *J. Exp. Med.* 165:381-394, 1987.
- Horowitz J, JE Volanakis, DE Briles: **Blood clearance of *Streptococcus pneumoniae* by C-reactive protein.** *J. Immunol.* 138:2598-2603, 1987.
- Briles DE, G Scott, B Gray, MJ Crain, M Blaese, M, Nahm, P Haber, V Scott, C Commer: **Naturally occurring antibodies to a phosphocholine potential index of antibody responsiveness to polysaccharides** *J. Infect. Dis.* 155:1307-1313, 1987.
- Scott MG, DE Briles, PG Shackelford, DS Smith, MH Nahm: **Human antibodies to phosphocholine: IgG anti-PC antibodies express restricted numbers of V and C regions.** *J. Immunol.* 138:3325-3331, 1987.
- Lal RB, RR Paranjape, DE Briles, TB Nutman, EA Otteson: **Circulating parasite antigen(s) in lymphatic filariasis; use of monoclonal antibodies to phosphocholine for immunodiagnosis.** *J. Immunol.* 138:3454-3460, 1987.
- McDaniel LS, WD Waltman II, B Gray, DE Briles: **A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid.** *J. Microbial Pathogenesis.* 3:249-260, 1987.
- Svanborg-Eden C, R Shahin, DE Briles: **Host resistance to mucosal and systemic gram-negative infection, susceptibility of lipopolysaccharide non-responder mice.** *J. Immunol.* 140:3180-3185. 1988.
- Waltman WD II, BM Gray, LS McDaniel, DE Briles: **Cross-reactive monoclonal antibodies in the diagnosis of pneumococcal meningitis.** *Clin. Micro.* 26: 1635-1640, 1988.
- Waltman WD II, LS McDaniel, B Andersson, L Bland, BM Gray, C Svanborg Eden, DE Briles: **Protein serotyping of *Streptococcus pneumoniae* based on reactivity to six monoclonal antibodies.** *Microbial Pathogenesis.* 5:159-167, 1988
- McDaniel LS, DE Briles: **A pneumococcal surface protein (PspB) that exhibits the same protease sensitivity as streptococcal R antigen.** *Infect and Immun.* 56: 3001-3003, 1988.
- Nordenstam G, B Anderson, C Bengtsson, DE Briles, G Scott, A Svanborg, E Svanborg: **Age related change in anticarbohydrate antibody levels.** *Am. J. Epidem.* 129: 89-96, 1989.
- Fallon MT, RB Shoeb, WH Benjamin Jr, JR Lindsey, DE Briles: **Modulation of resistance to *Salmonella typhimurium* infections in mice by mouse hepatitis virus (MHV).** *Microbial Pathogenesis.* 6:81-91, 1989.
- Briles DE, C Forman, JC Horowitz, JE Volanakis, WH Benjamin Jr, LS McDaniel, J Eldridge, J Brooks: **Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.** *Infection and Immunity.* 57: 1457-1464, 1989.
- Marion TN, ALM Bothwell, DE Briles, CA Janeway Jr: **IgG anti-DNA Autoantibodies within an individual autoimmune mouse are the products of clonal selection.** *J. Immunol.* 142:4269-4274, 1989.
- Berry AM, J Yother, DE Briles, D Hansen, JC Paton: **Reduced virulence of a defined Pneumo-lysin-negative mutant of *Streptococcus pneumoniae*.** *Infect Immun* 57: 2037 - 2042, 1989.
- Waltman WD II, LS McDaniel, BM Gray, DE Briles: **Variation in the molecular weight of PspA (Pneumococcal Surface Protein A) among *Streptococcus pneumoniae*.** *Microbial Pathogenesis* 8:61-69, 1990.
- Benjamin, WH Jr, P Hall, SJ Roberts, DE Briles: **The primary effect of the *lty* locus is on the rate of growth of *Salmonella typhimurium* that are relatively protected from killing.** *J. Immunol.* 144:3143-3151, 1990.
- Nordenstam G, B Andersson, D Briles, JW Brooks Jr, A Oden, A Svanborg, C Svanborg -Eden. **High anti-phosphorylcholine antibody levels and mortality associated with pneumonia.** *Scand. J. Infect. Dis.*, 22: 187-195, 1990.
- Crain MJ, WD Waltman II, JS Turner, J Yother, DF Talkington, LS McDaniel, BM Gray, DE Briles: **Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of *Streptococcus pneumoniae*.** *Infect. and Immun.*, 58: 3293-3299, 1990.
- McDaniel LS, JS Sheffield, P Delucchi, DE Briles: **PspA, a Surface Protein of *Streptococcus pneumoniae*, is capable of eliciting protection against pneumococci of more than one capsular type.** *Infect. and Immun.* 59: 222-228, 1991.

- Fallon MT, WH Benjamin Jr, TR Schoeb, DE Briles: **Mouse hepatitis virus strain UAB infection enhances resistance to *Salmonella typhimurium* in mice by inducing suppression of bacterial growth.** *Infect Immun.* 59: 852-867, 1991.
- Talkington DF, DL Crimmins, DC Voellinger, J Yother, DE Briles: **A 43 kDa Pneumococcal surface protein A (PspA): Isolation, Protective Abilities, and Structural Analysis of the Amino Terminal Sequence.** *Infect.and Immun.* 59: 1285-1289, 1991.
- Waltman WD, BM Gray, C Svanborg, R Facklam, DE Briles: **Epidemiologic studies of group 9 pneumococci in terms of protein type and 9N vs 9V capsular type.** *J. Infect. Dis.* 163: 812-818, 1991.
- Vakil M, DE Briles, JF Kearney: **Antigen independent selection of T15 idiotype during B-cell ontogeny in mice.** *Develop.Immunol.* 1:203-212, 1991.
- Dunlap NE, WH Benjamin Jr, RD McCall Jr, AB Tilden, DE Briles: **A "safe site" for *Salmonella typhimurium* is within splenic cells during the early phase of infection in mice.** *Microbial Pathogenesis* 10: 297-310, 1991.
- Benjamin WH Jr, J Yother, P Hall, DE Briles. **The *Salmonella typhimurium* locus *mviA* regulates virulence in *Ity^S* but not *Ity^r* mice: functional *mviA* results in avirulence; mutant (nonfunctional) *mviA* results in virulence.** *J. Exp. Med.* 174:1073-1083, 1991.
- Benjamin WH Jr, P Hall, DE Briles: **A *hemA* mutation renders *Salmonella typhimurium* avirulent in mice, yet capable of eliciting protection against subsequent *S. typhimurium* infection.** *Microbial Pathogenesis.* 11: 289-295, 1991.
- Yother J, DE Briles. **Structural and evolutionary relationships of PspA, a surface protein of *Streptococcus pneumoniae*, as revealed by sequence analysis.** *J. Bacteriol.* 174: 601-609, 1992.
- Yother J, GL Handsome, DE Briles. **Truncated forms of PspA that are secreted from *Streptococcus pneumoniae* and their use in functional studies and cloning of the *pspA* gene.** *J. Bacteriol.* 174: 610-618, 1992.
- Briles DE, MJ Crain, BM Gray, C Forman, J Yother: **A strong association between capsular type and virulence for mice among human isolates of *Streptococcus pneumoniae*.** *Infect. Immun.* 60: 111-116, 1992.
- Waltman WD II, DF Talkington, AE Lipinski, MJ Crain, JMS Dixon, Briles DE: **Evidence for a clonal origin of relative penicillin resistance among type 9L pneumococci in northwestern Canada.** *J. Infect. Dis.* 165: 671-675, 1992.
- Briles DE, C Forman, MJ Crain: **Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of *Streptococcus pneumoniae*.** *Infect. and Immun.* 60:1957-1962, 1992.
- Kraft, AS, V. Adler, P. Hall, GR Pettit, WH Benjamin Jr, DE Briles. **In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to *Salmonella typhimurium*.** *Cancer. Res.* 52:2143-2147, 1992.
- Munoz, R, JM Musser, M Crain, D Briles, A Marton, A Parkinson, U Sorensen, A Tomasz. **Geographic Distribution of four penicillin resistant clones of *Streptococcus pneumoniae*.** *Clin. Infect. Dis.* 15:112-118, 1992.
- Dunlap NE, WH Benjamin Jr, AK Berry, JH Edlridge, DE Briles: **A "safe-site" for *Salmonella typhimurium* is within splenic polymorphonuclear cells.** *Microbial Pathogenesis* , 13: 181-190, 1992.
- McDaniel LM, JS Sheffield, E Swiatlo, J Yother, MJ Crain, DE Briles: **Molecular localization of variable and conserved regions of *pspA*, and identification of additional *pspA* homologous sequences in *Streptococcus pneumoniae*.** *Microbial Pathogenesis.*, 13: 261-269, 1992.
- Talkington, DF, DC Voellinger, LS McDaniel, DE Briles: **Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane.** *Microbial Pathogenesis.* 13:343-355, 1992.
- Dunlap NE, S Ballinger, TE Reed, JC Christian, WJ Koopman, DE Briles : **The use of monozygotic and dizygotic twins to estimate the effects of inheritance on the levels immunoglobulin isotypes and antibodies to phosphocholine.** *Clin. Immuno. Immunopath.* 66:176-180, 1993.

- Dunlap NE, DE Briles: **Immunology of Tuberculosis.** *Clinics of Chest Medicine* 77:1235-1251, 1993.
- Langerman S, SR Palaszynski, S Koenig, M Hanson, JE Burlein, DE Briles, CK Stover. **Protective humoral response against pneumococcal infection in mice elicited by a recombinant Bacille Calmette-Guérin vaccines expressing PspA.** *J. Exp. Med.* 180:2277-2286, 1994.
- McDaniel LS, BA Ralph, DO McDaniel, and DE Briles. **Localization of protection eliciting epitopes on PspA (Pneumococcal Surface Protein A) of *Streptococcus pneumoniae*.** *Microbial Pathogenesis.* 17: 323-337. 1994
- Benton KA, MP Everson, DE Briles, **A pneumolysin-negative mutant of *Streptococcus pneumoniae* causes chronic bacteremia rather than acute sepsis in mice.** *Infect. and Immun.* 63:448-455, 1995.
- Szalai, AJ, DE Briles, JE Volanakis. **Human C-reactive protein is protective against *Streptococcus pneumoniae* infection in transgenic mice.** *J. Immunol.* 155:2557-2563, 1995.
- Tart, RC, LS McDaniel, BA Ralph, DE Briles. **Truncated *Streptococcus pneumoniae* PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice.** *J. Infect. Dis.* 173: 380-393, 1996
- Briles DE, JD King, MA Gray, LS McDaniel, E Swiatlo, KA Benton. **PspA, a protection-eliciting pneumococcal protein: Immunogenicity of isolated native PspA in mice.** *Vaccine.* 14: 858-67. 1996
- Crain MJ, JS Scott, DA Robinson, TJ Coffey, A Brooks-Walter, LS McDaniel, DE Briles. **Evidence for the simultaneous expression of two PspAs by a clone of capsular serotype 6B *Streptococcus pneumoniae*.** *Microbiol. Patho.* 21: 265-275. 1996.
- Swiatlo, E, MJ Crain, LS McDaniel, A Brooks-Walter, JS Sheffield, TJ Coffey, BG Spratt, DA Morrison, DE Briles. **DNA polymorphisms and variant penicillin-binding proteins as evidence that relatively penicillin-resistant pneumococci in western Canada are clonally related.** *J. Infect. Dis.* 174: 888-890. 1996
- Szalai AJ, DE Briles, JE Volanakis. **The role of complement in C-reactive-protein-mediated protection of mice from *Streptococcus pneumoniae*.** *Infect. Immun.* 64:4850-4853, 1996.
- Cartner SC, JW Simeka, DE Briles, GH Cassell, R Lindsey. **Resistance of mice to murine respiratory mycoplasmosis is a complex genetic trait.** *Infect. Immun.* 64:5326-5331, 1996.
- Yamamoto M, LS McDaniel, K Kawabata, DE Briles, RJ Jackson, JR McGhee, H Kiyono. **Oral immunization with PspA elicits protective humoral immunity against *Streptococcus pneumoniae* infection.** *Infect. Immun.* 65:640-644, 1997.
- Benton KA, JC Paton, DE Briles. **Differences in virulence for mice among *Streptococcus pneumoniae* strains of capsular types 2,3,4,5, and 6 are not attributable to differences in pneumolysin production.** *Infect. Immun.* 65:1237-1244, 1997.
- Wu H-Y, M Nahm, Y Guo, MW Russell, DE Briles **Intranasal immunization of mice with PspA (Pneumococcal surface protein A) can prevent carriage, and infection with *Streptococcus pneumoniae*.** *J. Infect. Dis.* 175:839-846, 1997.
- McDaniel LS, F Loechel, C Benedict, T Greenway DE Briles, RM Conry, DT Curiel. **Immunization with a plasmid expressing Pneumococcal Surface Protein A (PspA) can elicit protection against fatal infection with *Streptococcus pneumoniae*.** *Gene*, 375-377, 1997.
- Swiatlo E, A Brooks-Walter, DE Briles, LS McDaniel. **Oligonucleotides identify conserved and variable regions of *pspA* and *pspA*-like sequences of *Streptococcus pneumoniae*.** *Gene*, 189 (2): 279-284, 1997.
- Wu H-Y, A Virolainen, J King, MW Russell, DE Briles. **Establishment of a *Streptococcus pneumoniae* nasopharyngeal colonization model in adult mice.** *Microb. Pathogenesis* 23:127-137, 1997.
- Saladino RA, AM Stack, GR Gleisher, CM Thompson, DE Briles, L Kobzyk, GR Siber. **Development of a model of low-innoculum vaccine-type *Streptococcus pneumoniae* infection in infant rats.** *Infect. Immun.* 64:4701-4704, 1997.
- Benton KA, JC Paton, and DE Briles. **The hemolytic and complement-activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia model.** *Microb. Pathogen.* 23:201-209, 1997.
- Wortham C, L Grinberg, DC Kaslow, DE Briles, LS McDaniel, A Lees, M Flora, CM Snapper, JJ Mond.

- Enhanced protective antibody responses to PspA after intranasal or subcutaneous injection of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2.** *Infect. Immun.* 66:1513-1520. 1998.
- Benton KA, VanCott, JL, Briles DE. **Role of Tumor Necrosis Factor Alpha in the Host Response of Mice to Bacteremia Caused by Pneumolysin-Deficient *Streptococcus pneumoniae*.** *Infect. Immun.* 66:839-842. 1998..
- Nayak AR, SA Tinge, RC Tart, LS McDaniel, DE Briles, R Curtiss III. **A live recombinant avirulent oral *Salmonella* vaccine expressing pneumococcal surface protein A (PspA) induced protective responses against *Streptococcus pneumoniae*.** *Infect. Immun.* 66:3744-3751. 1998.
- Robinson DA, SK Hollingshead, JM Musser, AJ Parkinson, DE Briles, MJ Crain. **The IS1167 insertion sequence is a phylogenetically informative marker among isolates of serotype 6B *Streptococcus pneumoniae*.** *J. Mol. Evol.* 47:220-229. 1998.
- McDaniel LS, DO McDaniel, SK Hollingshead, DE Briles. **Comparison of the PspA sequence from *Streptococcus pneumoniae* EF5668 to the previously identified PspA sequence from strain Rx1 and the ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types.** *Infect. Immun.* 66:4748-4754,1998.
- Yamamoto M, DE Briles, S Yamamoto, M Ohmura, H Kiyono, JR McGhee. **A non-toxic adjuvant of mucosal immunity to pneumococcal surface protein A.** *J. Immunol.* 161: 4115-4121. 1998.
- Robinson DA, JS Turner, RR Facklam, AJ Parkinson, RF Breiman, M Gratten, SK Hollingshead, DE Briles, MJ Crain. **Molecular characterization of a globally distributed lineage of serotype 12F *Streptococcus pneumoniae* causing invasive disease.** *J. Infect. Dis.* 179: 414-422. 1999.
- O'Brien DP, DE Briles, A Szalai, A-H Tu, I Sanz, MH Nahm. **Tumor necrosis factor alpha is important for survival from *S. pneumoniae* infections.** *Infect Immun.* 67: 595-601. 1999.
- White P, A Hermansson, C Svanborg D Briles, K Prellner. **Effects of active immunization with a pneumococcal surface protein (PspA) and locally applied antibodies in experimental otitis media.** *ORL* 61:206-211. 1999
- Circolo A, G Garnier, W Fukuda, X Wang, T Hidvegi, AJ Szalai, DE Briles, JE Volanakis, RA Wetsel, HR Colten. **Genetic disruption of the murine complement C3 promoter region generates deficient mice with extra-hepatic expression of C3 mRNA.** *Immunopharmacology* 42: 135-149. 1999.
- Wu Z-Q, Q Vos, Y Shen, A Lees, SR Wilson, DE Briles, WC Gause, JJ Mond, CM Snapper. **In vivo polysaccharide-specific IgG isotype responses to intact *Streptococcus pneumoniae* are T cell-independent and require CD40- and B7-ligand interactions.** *J. Immunol.* 163:659-667. 1999
- Tu A-H. RL Fulgham, MA McCarty, DE Briles, AJ Szalai. **Pneumococcal surface protein A (PspA) inhibits complement activation by *Streptococcus pneumoniae*.** *Infect. Immun.* 67: 4720-4724. 1999.
- Brooks-Walter A, DE Briles, SK Hollingshead. **The *pspC* gene of *Streptococcus pneumoniae* encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia.** *Infect. Immun.* 67:6533-6542. 1999.
- Jedrzejas MH, SK Hollingshead, J Lebowitz, L Chantalat, DE Briles, E Lamani. **Production and characterization of the functional fragment of pneumococcal surface protein A.** *Arch. Biochem. Biophys.* 1:116-125, 2000.
- Briles DE, E Ades, JC Paton, JS Sampson, GM Carlone, R Heubner, A Virolainen, E Swiatlo, SK Hollingshead. **Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of *Streptococcus pneumoniae*.** *Infect. Immun.* 68:796-800, 2000.
- Virolainen A, W Russell, M Crain, S Rapola, H Kaythy, DE Briles. **Human antibodies to pneumococcal surface protein A, PspA** *J. Ped. Infect. Dis.* 19:134-138, 2000.
- Hwang YI, M Nahm, DE Briles, D Thomas, JM Purkerson. **Acquired, but not innate, immune responses to *Streptococcus pneumoniae* are compromised by neutralization of CE40L.** *Infect. Immun.* 68:511-517, 2000.
- Nabors, GS, PA Braun, DJ Herrmann, ML Heise, DJ Pyle, S Gravenstein, M Shilling, LM Ferguson, SK Hollingshead, DE Briles, RS Becker. **Immunization of healthy adults with a single recombinant**

- pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.** *Vaccine* 18:1743-1754, 2000.
- De BK, JS Sampson, EW Ades, RC Huebner, DL Jue, SE Johnson, M Espina, AR Stinson, DE Briles, GM Carlone. **Purification and characterization of *Streptococcus pneumoniae* palmitoylated pneumococcal surface adhesin A expressed in *Escherichia coli*.** *Vaccine* 18:1811-1821, 2000.
- Nahm MH, De Briles, X Yu. **Development of a multi-specific opsonophagocytic killing assay.** *Vaccine* 18:2768-2771, 2000.
- Lipsitch M, JK Dykes, SE Johnson, EW Ades, J King, DE Briles, GM Carlone. **Competition among *Streptococcus pneumoniae* for intranasal colonization in a mouse model.** *Vaccine* 18:2859-2901, 2000.
- Park MK, DE Briles, MH Nahm. **A latex bead-based flow cytometric immunoassay capable of simultaneous typing of multiple pneumococcal serotypes (multi-bead assay).** *Clinical Diagnostic Laboratory Immunology* 7:486-489, 2000.
- Ogunniyi AD, RL Folland, DE Briles, SK Hollingshead, JC Paton. **Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against *Streptococcus pneumoniae*.** *Infect Immun* 68:3028-3033, 2000.
- Rapola S, V Jantti, R. Haikala, Syrjanen, GM Carlone, JS Sampson, DE Briles, MC Paton, AK Takala, TM Kilpi, H Kayhty. **Natural development of antibodies to pneumococcal proteins PspA, PsaA, and pneumolysin in relation to pneumococcal carriage and acute otitis media.** *J. Infect. Dis.* 182:1146-1152, 2000.
- Hollingshead SK, RS Becker, DE Briles. **Diversity of PspA: mosaic genes and evidence for past recombination in *Streptococcus pneumoniae*.** *Infect. Immun.* 68:5889-5900, 2000.
- Briles DE, SK Hollingshead, J King, A Swift, PA Braun, MK Park, LM Ferguson, MH Nahm, GS Nabors. **Immunization of humans with rPspA elicits antibodies which passively protect mice from fatal infection with *Streptococcus pneumoniae* bearing heterologous PspA.** *J. Infect. Dis.* 182:1694-1701, 2000.
- Buchanan RM, DE Briles, BP Arulanandam, MAJ Westrunk, RH Reader, DW Metzger. **IL-12 mediated increase in protection elicited by pneumococcal and meningococcal conjugate vaccines.** *Vaccine* 19:2020-2028, 2001.
- Hakansson A, H Roche, S Mirza, LS McDaniel, A Brooks-Walter, DE Briles. **Characterization of the binding of human lactoferrin to pneumococcal surface protein A (PspA).** *Infect. Immun.* 69:3372-3381, 2001.
- Robinson DA, KM Edwards, KB Waites, DE Briles, MJ Crain, SK Hollingshead. **Population Structure of *Streptococcus pneumoniae* isolated from young children in central Tennessee.** *J. Infect. Dis.* 183:1501-1507, 2001.
- Balachandran P, SK Hollingshead, JC Paton, DE Briles. **The autolytic enzyme LytA of *Streptococcus pneumoniae* is not responsible for releasing pneumolysin.** *J Bacteriol.* 183:3108-3116, 2001.
- Depiero A, DA Karminski, JF Halsey, DE Briles, PD Burrows, RW Hostoffer. **Immunological compensation in a patient with a large IgH constant region deletion.** *J. Allergy Clin. Immunol.* 107:1051-1055. 2001
- Malley, R, M Lipsitch, A. Stack R Saladino, G Fleisher, S Pelton, C Thompson, D Briles P Anderson. **Use of a killed, whole-cell unencapsulated pneumococcal preparation as a mucosal vaccine to prevent nasopharyngeal colonization and invasive disease due to encapsulated pneumococci.** *Infect Immun* 69. 4870-4873. 2001.
- Strand TA, DE Briles, HK Gjessing, A Maage, MK Bhan, H Sommerfelt. **Pneumococcal Pulmonary Infection, Septicemia and Survival in Young Zinc Depleted Mice.** *British J. Nutrition.* 86:301-306. 2001.
- Arulanandam BP, JM Lynch, DE Briles, S Hollingshead, DW Metzger. **Intranasal vaccination with pneumococcal surface protein A and IL-12 augments antibody-mediated opsonization and protective immunity against *Streptococcus pneumoniae* infection.** *Infect. Immun.* 69:6718-2724. 2001.
- Coral MCV, N Fonseca, E Castaneda, JL Di Fabio, SK Hollingshead, DE Briles. **Families of Pneumococcal Surface Protein A (PspA) of *Streptococcus pneumoniae* Invasive Isolates Recovered from Colombian Children.** *Emerging Infectious Diseases.* 7:832-836. 2001.

- Smith AW, H Roche, M-C Trombe, DE Briles, A Håkansson. **Characterization of the dihydrolipoamide dehydrogenase from *Streptococcus pneumoniae* and its role in bacterial infection.** *Mol. Microbiol.* 44(2):431-448, 2002.
- Balachandran P, A Brooks-Walter, A Virolainen-Julkunen A, SK Hollingshead, and DE Briles. **The Role of Pneumococcal Surface Protein C (PspC) in Nasopharyngeal Carriage and Pneumonia and Its Ability to Elicit Protection Against Carriage of *Streptococcus pneumoniae*.** *Infect. Immun.* 70:2526-2534, 2002.
- Smith AW, H Roche, M-C Trombe, DE Briles, A Hakansson. **Characterization of the dihydrolipoamide dehydrogenase from *Streptococcus pneumoniae* and its role in bacterial infection.** *Mol. Microbiol.* 44:431-448, 2002.
- Robinson DA, De Briles, MJ Crain, SK Hollingshead. **The evolution and virulence of serogroup 6 pneumococci on a global scale.** *J. Bacteriol.* 184:6367-6375, 2002.
- Haas KM, M Hasegawa, DA Steeber, CJ Poe, MD Zebel, CB Bock, DR Karp, DE Briles, JH Weis, TF Tedder. **Complement receptor CD21/35 links innate and protective immunity during *Streptococcus pneumoniae* infection by regulating IgG3 antibody responses.** *Immunity* 17:713-713, 2002.
- Ren B, AJ Szalai, O Thomas, SK Hollingshead, DE. **Both family 1 and family 2 PspAs can inhibit complement deposition and confer virulence to a capsular 3 serotype *Streptococcus pneumoniae*.** *Infect. Immun.* 71:75-85, 2003.
- Roche H, A Hakansson, SK Hollingshead, DE Briles. **Regions of PspA.EF3296 best able to elicit protection against *Streptococcus pneumoniae* in a murine infection model.** *Infect. Immun.* 71: 1033-1041. 2003.
- Yu J, DE Briles, JA Englund, SK Hollingshead, WP Glezen, MH Nahm. **Immunogenic protein contaminants in pneumococcal vaccines.** *J. Infect. Dis.* 187:1019-1023. 2003
- Strand TA, SK Hollingshead, K Julshamn, DE Briles, B Blomberg, H Sommerfelt. **Effects of zinc deficiency and Pneumococcal Surface Protein A Immunization on zinc status and risk of severe infection in mice.** *Infect. Immun.* 71. 2009-2013. 2003
- David E. Briles, Susan K. Hollingshead, James C. Paton, Edwin W. Ades, Lea Novak, Frederik W. van Ginkel, and William H. Benjamin Jr. **Immunization with PspA and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with *Streptococcus pneumoniae*.** *J. Infect. Dis.* 188: 339-348. 2003.
- Roche H, B Ren, LS McDaniel, A Hakansson, DE Briles. **Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of *Streptococcus pneumoniae*.** In press June 2003. *Infect. Immun.* 71:4498-4505. 2003.
- Lynch M, DE Briles, DW Metzger, **Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus IL-12.** *Infection Immunity*, 2 71:4780-4788. 2003.
- Swiatlo E, J King, GS Nabors, B Mathews, DE Briles. **Pneumococcal Surface Protein A (PspA) is Expressed In Vivo and Antibodies to PspA are Effective Therapy in a Murine Model of Pneumococcal Sepsis.** In Press *Infection Immunity*. 2003.
- van Ginkel F, W, JR McGhee, JM Watt, A Campos-Torres, LA Parish, DE Briles. **Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection.** *PNAS* 100:13263-13267. 2003.
- Ren B. AJ Szalia, SK Hollingshead, Briles DE. **Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.** *Infect. Immun.* 72: 114-122. 2004
- Baril L, DE Briles, P Crozier, JD King, SK Hollingshead, TF Murphy JB McCormick. **Natural mother to infant transfer of antibodies to PspA and to PsaA.** (*British Journal of Clinical and Experimental Immunology* 135: 474-477. 2004.
- Mollerach M, M Regueira, L Bonofiglio, R Callejo, J Pace, JL Di Fabio, S Hollingshead, D Briles, and *Streptococcus pneumoniae* Working Group. **Invasive *Streptococcus pneumoniae* isolates from Argentinean children: serotypes, families of Pneumococcal Surface Protein A (PspA), and genetic diversity.** *Epidemiology and Infection* 132:177-184. 2004.

- Mirza S, SK Hollingshead, WH Benjamin Jr., DE Briles. **PspA protects streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin.** *Infect. Immun.* 72:5031-5040. **2004.**
- Johnston JW, LE Myers, MM Ochs, WH Benjamin, DE Briles, SK Hollingshead. **Lipoprotein PsaA in virulence of Streptococcus pneumoniae: surface accessibility and role in protection.** *Infect. Immun.* 72:5858-5867. **2004**
- Baril L, D Briles, P Crozier, J King, M Punar, S Hollingshead, J McCormick. **Antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease.** *Vaccine*, 23:789-93, **2004.**
- Ren B, MA McCorry, C Pass, DC Bullard, CM Ballantyne, Yuanyuan Xu, DE Briles, AJ Szalai. **The virulence function of Streptococcus pneumoniae surface protein A (PspA) involves inhibition of complement activation and impairment of complement receptor-mediated protection.** *J. I.* 173:7506-7512, **2004.**
- Palaniappan R, S Singh, E Ades, DE Briles, S Hollingshead, J Paton, J Sampson, and J Lillard. **Differential PsaA, PspA, PspC and PdB mucosal and systemic immunity.** *Infect. Immun* 73 (2):1006-1013. **2005.**
- Gor, DO, D Xuedong, DE Briles, MR Jacobs, NS Greenspan. **Relationship between surface accessibility for PpmA, PsaA, PspA and antibody mediated immunity to systemic infection by Streptococcus pneumoniae.** *Infect. Immun.* 73:1304-1312, **2005.**
- Payne DB, A Sun, JC Butler, SP Singh, S Hollingshead, DE Briles. **PspA family typing and PCR-based DNA fingerprinting with BX A1R primer of pneumococci from the blood of patients in the USA with and without sickle cell disease.** *Epidemiology and Infection*, **2005.**
- Gor, DO, X Ding, DE Briles, MR Jacobs, NS Greenspan. **Relationship between surface accessibility for PpmA, PsaA, PspA and antibody mediated immunity to systemic infection by Streptococcus pneumoniae.** *Infect. Immun.* 73: 1304-1312, **2005.**
- Johnson CN, DE Briles, WH Benjamin, SK Hollingshead, KB Waits. **Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae.** *Emerging Infectious Diseases*, 11:814-820. **2005.**
- Coats MT, WH Benjamin Jr, SK Hollingshead, DE Briles. **Antibodies to the pneumococcal surface protein A, PspA, can be produced in splenectomized mice and can protect splenectomized mice from infection with Streptococcus pneumoniae.** *Vaccine*. 23:4257-4262. **2005**
- Briles DE, L Novak, M Hotomi, FW van Ginkel, J King. **Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci.** *Infect. Immun.* 73:6945-6951 **2005.**
- Johnston JW, DE Briles, LE Myers, SK Hollingshead. **Mn2+-dependent regulation of multiple genes in Streptococcus pneumoniae through PsaR and the resultant impact on virulence.** *Infect. Immun.* 74: 1171-1180. **2006.**
- Hollingshead, SK, L Barill, S Ferro, J King, P Coan, DE Briles and the pneumococcal proteins Epi Study Group. **Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries.** *J. Med. Microbiol.* 55: 215-221. **2006.**
- Palaniappan R, S Singh, UP Singh, R Singh, EW Ades, DE Briles, SK Hollingshead, W Royal III, JS Sampson, JK Stiles, DD Taub, JW Lillard Jr. **CCL5 Modulates Pneumococcal Immunity and Carriage.** *J. Immunol.* 176:2346-2356. **2006.**
- Daniels CC, TC Briles, S Mirza, AP Håkansson, DE Briles. **Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae.** *Microbial Pathogenesis* 40:228-233. **2006.**
- Bernstein, JM, E Hasse, F Scannapieco, D Dryja, J Wolf, D Briles, J King, GE Wilding. **Bacterial interference of penicillin-sensitive and -resistant Streptococcus pneumoniae by Streptococcus oralis in adenoid organ culture: Implications for the treatment of recurrent upper respiratory tract infections in children and adults.** *Annals of Otolaryngology Rhinology & Laryngology* 115:350-356. **2006.**
- Baril L, J. Dietemann, M Essevez-Roulet, L Beniguel, P Coan, DE Briles, B Guy, G Conzon. **Pneumococcal surface protein A (PspA) is effective at eliciting C-cell-mediated responses during invasive pneumococcal disease in adults.** *Clinical and Experimental Immunology*, 145:277-286. **2006.**

- Simell B, T Jaakkola, M Lahdenkari, D Briles, S. Hollingshead, TM Kilpi, H Kayhty. **Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis media.** *Clin Vaccine Immunol* 13:1177-1179. 2006.
- Ogunniyi AO, M Grabowicz, Briles DE, Cook Jan, Paton, JC. **Development of a Vaccine Against Invasive Pneumococcal Disease Based on Combinations of Virulence Proteins of *Streptococcus pneumoniae*.** *Infect. Immun.* 75: 350-357. 2007
- Ogunniyi, AD, KS LeMessurier, RMA Graham, JM Watt, DE Briles, UH Stroehrer, JC Paton. **Contribution of Pneumolysin, PspA and PspC (CbpA) to Pathogenicity of *Streptococcus pneumoniae* D39 in a Mouse Model.** *Infect. Immun.* 75: 1843-1851. 2007
- Senkovich O, WJ Cook, S Mirza, S Hollingshead, II Protasevich, DE Briles, D Chattopadhyay. **Structure of a complex of human lactoferrin N-lobe with pneumococcal surface protein A provides insight into microbial defense mechanism.** *J. Mol. Biol.* 370:701-713. 2007.
- Winter C, K. Taut, M. Sirvastava, F. Langer, M. Mack, DE Briles, JC Paton, R Maus, T Welt, MD Gunn, UA Maus. **Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defenses of *Streptococcus pneumoniae* infection in mice: role of the CCL-CCR2 axis.** *J. Immunol* 178:5828-5823. 2007.
- Maus UA, M Backi, C Winter, M Sirvasta, MK Schwrz, T Ruckel, JC Paton, D Briles, M Mack, T Welt, R Maus, RM Bohle, W Seeger, C Rommel, E Hirsch, J Lohmeyer, KT Preissner. **Importance of phosphoinositide 3-kinase gamma in host defense against pneumococcal infection.** *Am. J. Respir. Crit. Care Med.* 75:958-966. 2007.
- Li J, LG, Cowden, JD King, DE Briles, HW Schroeder, AB Stevens, RT Perry, Z Chen, MS Simmons, HW Wiener, H Tiwari, LE. Harrell, RCP Go. **Effects of chronic stress and Interleukin-10 gene polymorphisms on antibody responses to tetanus vaccine in family caregivers of patients with Alzheimer's Disease.** In Press. *Psychosomatic Medicine* 69:000-000. 2007.
- Simell B, M Merit, M Lahdenkari, DE Briles, SK Hollingshead, TM Kilpi, H Kayhty. **Antibodies to pneumococcal surface protein A (PspA) families 1 and 2 in serum and saliva of children and the risk of pneumococcal AOM.** *J. Infect. Dis.* 1528-1536. 2007.
- Basset A, MC Thompson, SK Hollingshead, DE Briles, EW Ades, Lipsitch, R Malley, **Antibody-independent CD4+ T cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins.** *Infect. Immun.* 75:5460-5464. 2007.
- Winter C, K Taut, F Langer, M Mack, DE Briles, JC Paton, R Maus, M Sirvastava, T Welte, UA Maus. **FMS-Like Tyrosine Kinase 3 Ligand Aggravates the Lung Inflammatory Response to *Streptococcus pneumoniae* Infection in Mice: Role of Dendritic Cells.** *J. Immunol.* 179:3099-3018. 2007.
- Lim JH, B Stirling, J Derry, T Koga, H Jono, CH Woo, H Xu, P Bourne, UH Ha, H Ishinaga, H Xu, Y Huang, W Zhang, X Weng, C Yan, Z Zin, DE Briles, JR Davis, RA Flavell, JD Li. **Tumor suppressor CYLD regulates acute lung injury in lethal *Streptococcus pneumoniae* infections.** *Immunity* 27:349-360. 2007.
- Li J, DT Glover, AJ Szalai, SK Hollingshead DE Briles. **PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation.** *Infect. Immun.* 75:5877-5885. 2007
- Darrieux M, EN Miyaji, DM Ferreira, LM Lopes, APY Lopes APY, B Ren, DE Briles, SK Hollingshead, LCC Leite. **Fusion proteins containing family 1 and family 2 PspAs elicit protection against *Streptococcus pneumoniae* that correlates with antibody-mediated enhancement of complement deposition.** *Infect. Immun.* 75:5930-5938. 2007
- Hembre BSH, DE Briles, MS Harleen, HM Gerwal, TA Strand. **Effect of high dose oral zinc in mice with severe infection with *Streptococcus pneumoniae*.** *Scandinavian Journal of Infectious Diseases.* 40:363-367. 2007.
- Ochs MM, W Bartlett, DE Briles, B Hicks, A Jurkuvenas, P Lau , B Ren, and A Millar. **Vaccine-Induced Human Antibodies to PspA Augment Complement C3 Deposition on *Streptococcus pneumoniae*.** *Microb Pathog* 44:204-214, 2008.

- Taut K, C Winter, DE Briles, JC Paton, JW Christman, R Maus, R. Baumann, T Welte, AU Maus. **Macrophage turnover kinetics in the lungs of mice infected with *Streptococcus pneumoniae*.** *Am J Respir Cell Mol Biol.* 38:105-113. **2008.**
- Glover DT, SK Hollingshead, DE Briles. ***Streptococcus pneumoniae* surface protein PcpA elicits protection against lung infection and fatal sepsis.** *Infect Immun* 76:2767-2776 **2008.**
- Denzel A, U Maus, MR Gomez, C Moll, M Niedermeier, C Wintere, R Maus, S Hollingshead, DE Briles, LA Kunz-Schughart, Y Talke, M Mack. **Basophils enhance immunological memory responses.** *Nature Immunology* 9:733-742. **2008.**
- Schachern P, V Tsuprun, S Cureoglu, P Ferrieri, D Briles, M Paparella, S Juhn. **The round window membrane in otitis media: effect of pneumococcal proteins.** *Arch Otolaryngol Head Neck Surg.* 134:658-652. **2008.**
- Torii I, O Satoshi, M Hotomi, WH Benjamin Jr., T Takai, JF Kearney, DE Briles, H Kubagawa. **PIR-B deficient mice are susceptible to salmonella infection.** *J Immunol* 181:4229-4239 **2008.**
- Melin MM, SK Hollingshead, DE Briles, MI Lahdenkari, TM Kilpi, HM Kaythy. 2008. **Development of antibodies to PspA family 1 and 2 in children after exposure to *Streptococcus pneumoniae*.** *Clin Vaccine Immunol* 15:1529-1535. **2008.**
- Melin MM, SK Hollingshead, DE Briles, WP Hanage, M Lahdenkari, T Kaijalainen, TM Kilpi, HM Kaythy. 2008. **Distribution of pneumococcal surface protein A families 1 and 2 among *Streptococcus pneumoniae* isolates from children in Finland who had acute otitis media or were nasopharyngeal carriers.** *Clin. Vaccine Immunol.* 15:1555-1563. **2008.**
- Tsuprun V, S Cureoglu, PA Schachren, P Ferrieri, DE Briles, MM Paparella, SK Juhn. **Role of Pneumococcal Proteins in Sensorineural Hearing Loss Due to Otitis Media.** *Otol Neurotol* 29:1056-1060. **2008.**
- Li J, AJ Szalai, SK Hollingshead, MH Nahm, DE Briles. **Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages.** *Infect Immun.* 77:464-471. **2009.**
- Arevalo M, Q Xu, JC Paton, S. Hollingshead, M Pichichero, D Briles, N Girgis, M Zeng M. **Mucosal vaccination with a multi-component adenovirus-vectored vaccine protects against *Streptococcus pneumonia* infection in the lung.** *FEMS Immunol Medl Microbiol* 55:346-351. **2009.**
- Shah P, Briles DE, King K, Hale Y, Swiatlo, E. **Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with *Streptococcus pneumoniae*.** *Exp Biol Med* 234:403-409. **2009**
- Winter C, Herbold W, Regina M, Langer F, Briles DE, Paton JC, Welte T, Maus UA. **Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to sepsis in mice infected with *S. pneumoniae*.** *J Immunol,* 182:4931-4937. **2009.**
- Schachern PA, V Tsuprun, S Cureoglu, P Ferrieri, DE Briles, MM Paparella, S Juhn. **Virulence of pneumococcal proteins in the inner ear.** *Arch Otolaryngol Head Neck Surg.* 135:657-661. **2009.**
- Henken S, J Bohling, JC Paton, D Ogunniyi, DE Briles, VC Salisbury, D Wedekind, T Welte, UA Maus. **Efficacy profile of daptomycin for the treatment of invasive as compared to non-invasive pulmonary infections with *S. pneumoniae*.** *Antimicrob Agents Chemother.* 54:707-717. **2010**
- Diavatopoulos DA, KR Short, JT Price, JJ Wilksh, LE Brown, DE Briles, RA Strugnell, OL Wijburg. **Influenzae A virus facilitates *Streptococcus pneumoniae* transmission and disease.** *The FASEB Journal.* On Line 100122. **2010**
- Singh R, S Singh, PK Sharma, UP Singh, DE Briles, SK Hollingshead, JW Lillard Jr. **Helper T cell epitope mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.** In Press *PLOS One*. 2010.
- Daniels CC, P Coan, J King, J Hale, K Benton, DE Briles, SK Hollingshead. **The proline-rich region of pneumococcal surface proteins A and C contains surface accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.** *Infect. Immun.* 78:2163-72 **2010.**

- Herbold W, R Maus, I Hahn, M Srivastava, M Mack, C Winter, DE Briles, JC Paton, T Welte, UA Maus. **Important role of CXC chemokine receptor 2 (CXCR2) in neutrophil-exudate macrophage-dependent immunity against *S. pneumoniae*.** *Infect. Immun.* In Press. April 6, 2010.
- Ferreira DM, MLS Oliveira, AT Moreno, PL Ho, DE Briles, EN Miyaji. **Protection against nasopharyngeal colonization with *Streptococcus pneumoniae* by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal Surface Protein A).** *Microbial Pathogenesis* 48:205-215. 2010
- Li J, Wang J, Ghiran I, Cerny A, Szalai AJ, Briles DE, Finberg RW. **CR1 expression on mouse erythrocytes mediates clearance of *Streptococcus pneumoniae* by immune adherence.** *Infect. Immun.* 78:3129-3135. In "Spotlight". 2010.
- Y Fukuyama, JD King, K Kataoka, Ri Kobayashi, RS Gilbert, K Oishi, SK Hollingshead, DE Briles, and K Fujihashi. **Secretory IgA antibodies play an important role in immunity to *Streptococcus pneumoniae*.** *J. Immunol* 185:1755-1782. In "In this issue" top 10% of papers. 2010
- Gwinn WM, SM Kirwan, SH Wang, KA Ashcraft, NL Sparks, CR Doil, TG Tlusty, LS Casey, SK Hollingshead, DE Briles, RS Donero, AJ Hickey, WM Foster, HF Staats. **Effective induction of protective systemic immunity with nasally-administered vaccines adjuvanted with IL-1.** *Vaccine* 28: 6901-6914. 2010.
- Schachren PA, V Tsuprun, S Cureoglu, PA Ferrieri, DE Briles, MM Paparella, SK Juhn. **Effect of apolactoferrin on experimental pneumococcal otitis media.** *Arch Otolaryngol Head Neck Surg.* 136:1127-1131. 2010
- Fukuyama Y, JD King, K Kataoka, R Kobayashi, RS Gilbert, SK Hollingshead, DE Briles, K Fujihashi. **A Combination of Flt3 Ligand cDNA and CpG Oligodeoxynucleotide as Nasal Adjuvant Elicits Protective Secretory-IgA Immunity to *Streptococcus pneumoniae* in Aged Mice.** *J. Immunol* 186:2454-2461. 2011.
- Arai J, M Hotomi, SK Hollingshead, Y Ueno, DE Briles, N Yamanaka. ***Streptococcus pneumoniae* isolated from middle ear fluid and nasopharynx of children with acute otitis media exhibit phase variation.** *J Clin Micro* 49:1646-1649. 2011.
- Coats MT, T Murphy, JC Paton, B Gray, DE Briles. **The exposure of Thomsen-Friedenreich Antigen in *Streptococcus pneumoniae* infection is dependent on pneumococcal neuraminidase A.** *Microbial Pathogenesis.* 50:343-349. 2011.
- Mirza S, L Wilson, WH Benjamin Jr, J Novak, S. Barns, SK Hollingshead, DE Briles. **Serine protease PrtA from *Streptococcus pneumoniae* plays a role in the killing of *S. pneumoniae* by apolactoferrin.** *Infect Immun* 79:2440-24450. 2011.
- Tran, TD, HY Kwon EH Kim, KW Kim, DE Briles, S. Pyo, DK Rhee. **Decrease in penicillin susceptibility due to heat shock protein ClpL in *Streptococcus pneumoniae*.** *Actinimicrob Agents Chemother* 55:2714-2728. 2011.
- Kataoka K, KFujihashi, K Oma, Y Fukuyama, SK Hollingshead, S Sekine, S Kawabata, HO Ito, DE Briles, K Oishi. **The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.** *Infect. Immun.* 79:2819-2828. 2011.
- Kono M, M Hotomi, SK Hollingshead, DE Briles, N Yamanaka. **Maternal immunization with Pneumococcal surface protein A protects against pneumococcal infections among derived offspring.** *PLoS ONE* 6:e27102. 2011.
- Kim EH, SY Choi, MK Kwon, TD Tran, SS Park, KJ Lee, SM Bae, DE Briles, DK Rhee. ***Streptococcus pneumoniae* pep27 mutant as a live vaccine for serotype-independent protection in mice.** *Vaccine* 30:2008-219. 2012
- Singh R, S Singh, DE Briles, DD Taub, SK Hollingshead, JW Lillard Jr. **CCL5-independent helper T lymphocyte response to immuno-dominant pneumococcal surface protein A epitopes.** *Vaccine* 30:1181-90. 2012
- Bieghs V, van Gorp PJ, Walenbergh S, Gijbels MJ, Verheyen F, Buurman WA, DE Briles, Hofker MH, Binder CJ, Shiri-Sverdlov R. **Specific immunization strategies against oxidized LDL: a novel way to reduce non-alcoholic steatohepatitis in mice.** *Hepatology* 56: 894-903. 2012.
- Weber M, S Lambeck, N Ding, S Henken, M Kohl, HP Deigner, DP Enot, L Frappart, M Kiehntopf, RA Claus, T

- Kamradt, D Weih, Y Vodovotz, DE Briles, AD Ogunniyi, JC Paton, UA Maus, M Bauer. **Hepatic induction of cholesterol biosynthesis reflects a remote adaptive response to pneumococcal pneumonia.** *FASEB J* (electronic March 12) **2012**.
- Croney CM, MT Coats, MN Nahm, DE Briles, MJ Crain. **PspA family distribution, unlike capsular serotype, remained unaltered following introduction of the heptavalent-pneumococcal conjugate vaccine.** *Clin Vaccine Immunol* 19:891-896. **2012**
- Park IH, K-H Kim, AL Andrade, DE Briles, LS McDaniel, MH Nahm. **Nontypeable Pneumococci Can Be Divided into Multiple cps Types, Including One Type Expressing the Novel Gene *pspK*.** 3:e00035-12 **2012**.
- Ren B, J Li, K Genschmer, SK Hollingshead DE Briles. **The absence of PspA or the presence of antibody to PspA each facilitate the complement-dependent phagocytosis of pneumococci *in vitro*.** *Clin Vaccine Immunol* 19:1574-1582. PMID: 22855389. **2012**.
- Mukerji R, S Mirza, AM Roche, RW Widener, CM Croney, DK Rhee, JN Weiser, AJ Szalai, DE Briles. **Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine.** *J Immunol* 189:5327-5335. **2012**.
- Vale AM, P Kapoor, G Skibinski, A. Elgavish, TI Mahmoud, C Zemlin, M Semlin, PD Burrows, A Noberga, JF Kearney, DE Briles, HW Schroeder Jr. **The link between antibodies to OxLDL and natural protection against pneumococci depends on DH gene conversation.** *J. Exp. Med.* 210:875-890. **2013**. PMID 3646500
- Kong IG, A Sato, Y Yuki, T Nochi, H Takahashi, S Sawada, M Mejima, S Kurokawa, K. Okada, S Sato, DE Briles, J Kunisawa, Y Inoue, M Yamamoto, K Akiyoshi, H, Kyono. **Nanogel-based PspA Intransal Vaccine Prevents Invasive Disease and Nasal Colonization by Pneumococcus.** *Infect Immun* 81:1625-1634. **2013**. PMID 3647999
- Choi SY, TD Tran, DE Briles, DK Rhee. **Inactivated *pep27* mutant as an effective mucosal vaccine against secondary lethal pneumococcal challenge in mice.** *Clin Exp Vaccine Res* 2:58-65. **2013**. PMID 3623503
- Hotomi M, A Togawa, M Kono, S Ikeda, SK Hollingshead, DE Briles, K Suzuki, N Yamanaka. **PspA family distribution, antimicrobial resistance and serotype of *Streptococcus pneumoniae* isolated from upper respiratory tract infections in Japan.** *PloS One* 8:e58124. **2013**. PMID 3590126
- Zhao H, JA Jung, DE Briles, H Kita, C. Tsigrelis, YJ Juhn. **Asthma and antibodies to pneumococcal virulence proteins.** *Infection* 41: 927-934. **2013**. PMID 3778049
- Haughney, LK Petersen, AD Schoofs, AE Ramer-Tait, JD King, DE Briles, MJ Wannemuehler, B Narasimhan. **Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.** *Acta Biomater* 9:8262-8271. **2013**.
- Daniels CC, K-H Kim, RL. Burton, S Mirza, M Walker, J King, Y Hale, P Coan, D-K Rhee, MH Nahm, and DE Briles. **Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A.** *Clin Vaccine Immunol* 20:1549-1558. **2013**.
- Croney CM, MH Nahm, SK Juhn, SK, DE Briles, MJ Cain. **Invasive and noninvasive *Streptococcus pneumoniae* capsule and surface protein diversity following use of conjugate vaccine.** *Clin Vaccine Immunol* 20:1711-1718. **2013**
- Schachern PA, V Tsuprun, S Goetz, S Cureoglu, SK Juhn, DE Briles, MM Papaella, P Ferrieri. **Viability and virulence of pneumolysin, pneumococcal surface protein A, and**

pneumolysin/pneumococcal surface protein A mutants in the ear. *JAMA Otolaryngol Head Neck Surg* 139:937-943. **2013.**

Genschmer, KR, MA Accavitti-Loper, DE Briles, **A Modified Surface Killing Assay (MSKA) as a Potential *in vitro* Surrogate Assay for Identifying Protective Antibodies Against Pneumococcal Surface Protein A (PspA).** *Vaccine*. 32:39-41. **2014.**

Bischof, A, C Brumshagen, N Ding, G Kirchhof, DE Briles, JE Gessner, T Welte, M Mack, AU Maus. **Basophil Expansion Protects Against Invasive Pneumococcal Disease in Mice,** *J. Infect Dis.* In Press March 2014.

Vadesilho CF, DM Ferreira, SB Gordon, DE Briles, AT Moreno, ML Oliveira, PL Ho, EN Miyaji. **Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA (Pneumococcal surface protein A) and PspC (Pneumococcal surface protein C).** *Clin Vaccine Immunol*. 21: 940-948. **2014** PMID 4097434.

Schachern PA, V. Tsuprun, P Ferrieri, DE Briles, S. Goetz, S Cureoglu, MA Paparella, S Juhn. **Pneumococcal PspA and PspC Proteins: Potential Vaccine Candidates for Otitis Media.** *Int J Pediatr Otorhinolaryngol*. 78:1517-1521. **2014.** PMID 4129636

Piao Z, Y Akeda, D Takeuchi, K Ishii, K Ubukata, DE Briles, K Tomono, K Oishi. **Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumonia caused by *Streptococcus pneumoniae* with five different PspA clades in mice.** *Vaccine*. In Press July 31, 2014.

Wade KR, ME Holtz, DE Briles, RK Tweten. **Mouse, but not human ApoB-100 lipoprotein cholesterol is a potent innate inhibitor of *Streptococcus pneumoniae* pneumolysin.** *Plos Pathogens*. 10:e1004353. 2014 PMID 4154877.

Kothari, N KR Genschmer, S Kothari, JA Kim, DE Briles, DK Rhee, and R Carbis **Preparation and testing of a Vi conjugate vaccine using pneumococcal surface protein A (PspA) from *Streptococcus pneumoniae* as the carrier protein.** *Vaccine*. 33:5755-5760. 2014.

Luong TT, Kim EH1, Bak JP, Nguyen CT, Choi S, DE Briles DE, Pyo S, Rhee DK. Ethanol-induced alcohol dehydrogenase E (AdhE) potentiates pneumolysin in *Streptococcus pneumoniae*. *Infect Immun*. 83:108-119. **2015**

Miyaji E, Vadesilho C, Oliveira ML, Zelanis A, DE Briles, Ho P. Evaluation of a vaccine formulation against *Streptococcus pneumoniae* based on choline-binding proteins. *Clin Vaccine Immunol* 22:213-220. **2015**

Kothari, N, S Kothari, YJ Choi, A Dey, DE Briles, DK Rhee, and R Carbis. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of *Streptococcus pneumoniae* strains and *Salmonella Typhi*. *Vaccine* 33:783-788. **2015.**

Fukuyama Y, Y Yuki, Y Katakai, N Harada, H Takahashi, S Takeda, M Mejima, S Joo, S Kurokawa, S Sawada, H Shibata, EJ Park, K Fujihashi, DE Briles, Y Yasutomi, H Tsukada, K Akiyoshi, HKiyono. Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against *Streptococcus pneumoniae* in macaques, January 2015 Accepted *Mucosal Immunology*.

Park SS, HY Kwon, TD Tran, MH Choi, SH Jung, S Lee, DE Briles, DK Rhee. ClpL is a chaperone without auxiliary factors. *FEBS J*. 282:1353-67. 2015

Chen, A. B. Mann, G. Gao, J. King, J. Maissoneuve, M. Alderson, A. Tate, S. K. Hollingshead, R. K.

- Tweten, D. E. Briles, E. I. Tuomanen, J. C. Paton. **Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysin with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.** *Clin Vaccine Immunol.* 22:1079-1089. **2015.** PMID 4580740.
- Dennis EA, MT Coats, SE Griffin, JY Hale, L Novak, DE Briles, MJ Crain. **The effects of CFTR and mucoid phenotype on susceptibility and innate immune responses in a mouse model of pneumococcal lung disease.** *PLoS ONE* 10:e0140355 **2015.** PMID 4607445
- Kim JY, JC Paton, DE Briles, DK Rhee, S Pyo. ***Streptococcus pneumoniae* induces pyroptosis through the regulation of autophagy in murine microglia.** *Oncotarget* In Press 2015, Accession Number 26683708. **2015**
- Walker, MM, L Novak, R Weidner, JA Grubbs, J King, JY Hale, MM Ochs, LE Myers, DE Briles, J Deshane. **PcpA Promotes Higher Levels of Infection and Modulates Recruitment of Myeloid-Derived Suppressor Cells during Pneumococcal Pneumonia.** *J Immunol.* 196:2239-48. PMID 4761482. **2016**
- Hotomi M, J Yuasa, DE Briles, N Yamanaka. **Pneumolysin plays a key role in the initial step of establishing nasal colonization.** *Folia Microbiol (Praha)* In Press 2016.

REVIEWS, CHAPTERS AND BOOKS

- Hansburg D, B Cleivinger, RM Perlmutter, R Griffith, DE Briles, JM Davie: **Analysis of the diversity of murine antibodies to a (1-3) dextran.** In: *Cells of Immunoglobulin Synthesis*. B. Pernis and P. Vogel, eds. Academic Press, Inc., NY, 1979. pp. 295-308.
- Briles DE, M Nahm, K Schroer, P Baker, J Davie: **Susceptibility of CBA/N X DBA/2 F₁ male mice to infection with type 3 *Streptococcus pneumoniae*.** Proceedings of the International Symposium of the Canadian Society for Immunology on Genetic Control of Natural Resistance to Infection and Malignancy, Montreal, March 18-20, 1980. In: *Perspective in Immunology*. E. Skamene, ed. Academic Press, Inc., 1980. pp. 173-177.
- Marion TN, DE Briles: **Analysis of autoimmune anti-DNA antibody responses using somatic cell hybridization.** In: *Monoclonal Antibodies and T Cell Hybridomas*, Vol. 3. J. F. Kearney, G. Hammerling and U. Hammerling, eds. Elsevier/North Holland Publishing Company, NY, 1981. pp. 251-258.
- Briles DE, LJ Claflin, K Schroer, C Forman, P Basta, J Lehmeyer, WH Benjamin Jr: **The use of hybridoma antibodies to examine antibody-mediated anti-microbial activities.** In: *Monoclonal Antibodies and T Cell Hybridomas*, Vol. 3. J. F. Kearney, G. Hammerling and U. Hammerling, eds. Elsevier/North Holland Publishing Company, NY, 1981. pp. 285-290.
- Kearney JF, DE Briles, MJ LeJeune: **A study of immunoglobulin diversity expressed by hybridomas made with pre-B cells and immature B lymphocytes.** In: *Monoclonal Antibodies and T Cell Hybridomas*, Vol. 3. J. F. Kearney, G. Hammerling and U. Hammerling, eds. Elsevier/North Publishing Company, NY, 1981. pp. 379-387.
- Briles DE, R Barletta, M Nahm, K Schroer, P Baker, JF Kearney: **Use of hybridoma technology to study anti-pneumococcal antibodies:** Anti-phosphocholine antibodies can protect mice against infection with type 3 *Streptococcus pneumoniae*. In: *Seminars in Infectious Diseases*. Vol. IV: *Bacterial Vaccines*. J. B. Robbins, J. C. Hill and J. C. Sadoff, eds. Thioeme-Stratton, Inc., NY, 1982. pp. 1-5.
- Cooper MD, P Haber, WE Gathings, M Mayumi, T Kuritani, DE Briles: **Deficient IgA synthesis viewed in the context of normal development of IgA B-cells.** *Annals, NY Acad. Sci.* 409:461-468, 1983.
- Svanborg-Eden, C, DE Briles, L Hagberg, J McGhee, S Michalek: **Genetic factors in host resistance to urinary tract infection.** *Infection* 12:118-123, 1984.
- McDaniel LS, DE Briles: **Protective effects of antibodies to pneumococcal cell wall proteins.** *Microbiology-1985*. D. Schillinger, ed. American Society for Microbiology, Washington, D. C. pp. 103-105, 1985.
- Briles DE, JF Kearney: **Idiotypic antibodies.** In: *Immunochemical Techniques, A Volume of Methods in Enzymology*. S. P. Colwich and N. O. Kaplan, eds. Academic Press, NY, 1985. Volume 116:174-189.
- Benjamin WH Jr, DE Briles: **Evidence that the Pathogenesis of *Salmonella typhimurium* is dependent on interactions between salmonella and mouse genotypes.** In: *Genetic Control of Host Resistance to Infection and Malignancy*. Emil Skamene, ed. Alan R. Liss, Inc., NY, 1985. pp. 239-244.
- Svanborg-Eden, C, L Hagberg, DE Briles, J McGhee, S Michalek: **Susceptibility to *Escherichia coli* urinary tract infection and LPS are responsiveness.** In: *Genetic Control of Host Resistance to Infection and Malignancy*. Emil Skamene, ed. Alan R. Liss, Inc., NY, 1985. pp. 385-391.
- Briles DE, Benjamin WH Jr and Posey B: **Use of recombinant inbred mice to study the genetics of disease resistance.** In: *2nd International Symposium on Genetic Control of Host Resistance to Infection and Malignancy*, 1985. Emil Skamene, ed. Alan R. Liss, Inc., NY, 1985. pp. 97-99.
- Briles, DE: **Genetic Control of the Susceptibility to Bacterial Infection.** D. E. Briles, ed. Springer-Verlag GmbH and Company, KG., 1986. Volumn 124.
- Briles DE, J Horowitz, LS McDaniel, WH Benjamin Jr, JL Claflin, CL Booker, G Scott, C Forman: **Genetic control of susceptibility to pneumococcal infection.** In: *Current Topics in Microbiology and Immunology: Genetic Control of the Susceptibility to Bacterial Infection*. D. E. Briles, ed. Springer-Verlag GmbH and Company, KG., 1986. pp. 103-120.
- Briles DE, WH Benjamin Jr, WJ Huster, B Posey: **Genetic approaches to the study of disease resistance; with special emphasis on the use of recombinant inbred mice.** In: *Current Topics in Microbiology and Immunology: Genetic Control of the Susceptibility to Bacterial Infection*. D. E. Briles, ed. Springer-Verlag

- GmnH and Company, KG., 1986. pp. 124:21-35.
- Briles DE, LS McDaniel, J Horowitz, CL Booker: **Protective effects of antibodies to non-capsular antigens of *Streptococcus pneumoniae*.** In: *Proceedings of the Bacterial Vaccine Symposium*, 1984. Bethesda, MD.
- McDaniel LS, DE Briles: **Monoclonal antibodies against surface components of *Streptococcus pneumoniae*.** In: *Monoclonal Antibodies Against Bacteria*. A. J. L. Marcario and E. C. de Macario, eds. Academic Press, NY, 1986. pp. 143-164.
- Briles DE, D Carroll: **Natural selection and the response to polysaccharides.** In: *Evolution and Vertebrate Immunity; the antigen receptor and MHC gene families*. G. Kelso and D. H. Schulze, eds. University of Texas Press, Austin, TX, 1987. pp. 117-133.
- McDaniel LS., J. Yother, WD Waltman II, DE Briles. **Insertionally inactivated mutants that lack pneumococcal surface protein A.** In: J. J. Ferretti and R. Curtiss, III, ed., *Streptococcal Genetics. Proceedings of the 2nd International Symposium of Streptococcal Genetics*. American. Soc. Microbiol., Washington, D.C., p. 172-176, 1987.
- Briles DE, J Yother, LS McDaniel: **The role of pneumococcal surface protein A in the virulence of *Streptococcus pneumoniae*.** In: *Proceedings of the 1986 meeting, Microbial Surfaces; Determinants of Virulence and Host Responsiveness*. Reviews of Infectious Diseases. 1988. pp. 372-374.
- Scott MG, PG Shackelford, DE Briles, MH Nahm: **Human IgG subclasses and their relation to carbohydrate antigen immunocompetence Diagnosis and Clinical Immunology.** 1988. 5:241-248.
- Scott MG, DE Briles, MH Nahm: **Selective IgG subclass expression: biologic, clinical and functional significance.** In: *Molecular Aspects of IgG Subclasses*. Editor, F. Shakib, Pergaman Press. pp 161-183. 1990.
- Benjamin WH Jr, WE Briles, DE Briles: **Effect of genetics and prior *Salmonella enteritidis* infection on the ability of chickens to be infected with *S. enteritidis*.** In, Colonization control of human bacterial enteropathogens in poultry, An international symposium. Atlanta, GA, September 27-29, 1989.24. In. Colonization control of human bacterial enteropathogens in poultry. Editor, LC Blankinship. Academic Press, Inc. San Diego, CA. pp 365-369, 1991.
- Yother J, LS McDaniel, MJ Crain, DK Talkington, DE Briles: **Pneumococcal surface protein A: Structural analysis and biological significance.** In: Genetics and molecular biology of streptococci, lactococci, and enterococci. Editor GM Dunny, PP Cleary, and LL McKay. American Society for Microbiology, Washington, D. C. pp. 88-91, 1991.
- WH Benjamin Jr, WE Briles, WD Waltman, DE Briles: **Effect of Genetics and prior salmonella enteritidis infection on the ability of chickens to be infected with *S. enteritidis*.** Colonization Control of Human Bacterial Enteropathogens in Poultry. Academic Press, N.Y. p365-369, 1991.
- Briles DB, NE Dunlap, E Swords, and WH Benjamin Jr: **Early events in the pathogenesis of enteric fever in mice.** in The Biology of Salmonella. Editor Felipe Cabello. Plenum Publishing Company, New York. in press 1992.
- Dunlap, NE, DE Briles: **Immunology of Tuberculosis.** Editor, John B. Bass. In Medical Clinics of North America Vol 77. No.6 1235-1251. 1993.
- Dunlap NE, WH Benjamin Jr, DE Briles. **Intracellular nature of salmonella infection during the early stages of mouse typhoid.** in Macrophage pathogen interactions. Eds B Zwilling and T. Eisenstein, Marcel Dekker Inc., New York, NY in press 1992.
- Ralph BA, DE Briles, LS McDaniel: **Cross-reactive protection eliciting epitopes of pneumococcal surface protein A.** Annals of the New York Acad. Sci. Vol.00:361-362. 1995.
- Russell WM, H-Y Wu, G Hajishengallis, E Harokopakis, DE Briles, SM Michalek, J Mestecky. **IgA antibodies and mucosal immune protection.** *Peridocium biologum* 98:513-420, 1996.
- Briles DE, RC Tart, H-Y Wu, BA Ralph, MW Russell, LS McDaniel. **Systemic and mucosal protective immunity to pneumococcal surface protein A.** New York Acad. Sci. 797:118-126, 1996.
- Briles DE, SK Hollingshead, E Swiatlo, A. Brooks-Walter, A Szalai, A Virolainen, LS McDaniel, KA Benton, P White, K Prellner, A Hermansson, PC Aerts, H Van Dijk, MJ Crain. **PspA and PspC: Their potential for**

- use as pneumococcal vaccines.** In the Proceedings of the 1996 International Workshop on *Streptococcus pneumoniae*. *Microb. Drug Resist* 3: 401-408. 1997
- Hollingshead SK, DE Bessen, DE Briles. **Archeological footprints of horizontal gene transfer: Mosaic cell surface proteins in *S. pyogenes* and *S. typhimurium*.** in "Horizontal Gene Transfer: Implications and Consequences. ed. M Syvanen C Kado. Chapman and Hall, London. pages 192-207. 1998.
- Briles DE, RC Tart, E Swiatlo, JP Dillard, P Smith, KA Benton, BA Ralph, A Brooks-Walter, MJ Crain, SK Hollingshead, LS McDaniel. **Pneumococcal diversity: considerations for new vaccine strategies with an emphasis on pneumococcal surface protein A (PspA).** *J. Clin. Microbiol Rev.* 11: 645-657. 1998
- Nahm MH, Apicella MA, Briles DE. **Immunity to Extracellular Bacteria:** Chapter 40, Fundamental Immunology, Edited by William Paul, 4th Edition, Lippincott-Raven Publishers, Philadelphia, pp 1373-1386. 1999.
- Prellner K, A Hermansson, P White, A Melhus, D Briles. **Immunization and protection in pneumococcal otitis media studies in a rat model.** *Microb. Drug Resist.* 5:73-82, 1999.
- Briles DE, JC Paton, MH Nahm, E Swiatlo. **Immunity to *Streptococcus pneumoniae*.** In: Effects of microbes on the immune system. Edited by MW Cunningham and RS Fujinami. Lippincott-Raven, Philadelphia, pages 263-280, 2000.
- Briles DE, E Swiatlo, K Edwards. **Vaccine Strategies for *Streptococcus pneumoniae*.** in Streptococci edited by Dennis L. Stevens. Oxford Univ. Press, New York, 419-433, 2000.
- Briles DE, SK Hollingshead, E Swiatlo, A Brooks-Walter, A Szalai, A. Virolainen, LS McDaniel, KA Benton, PC Aerts, H van Dijk, and Marilyn J Crain. **Pneumococcal Proteins PspA and PspC: Their potential use as vaccines.** Editors Alexander Tomasz and Robert Austrian Mary Ann Liebert Inc. Larchmont New York. 253-260, 2000.
- Briles, DE, JC Paton, E Swiatlo, MH Nahm. **Pneumococcal Vaccines.** In Gram Positive Pathogens Book, Edited by VA Fischetti. ASM Press, Washington, DC, 244-250, 2000.
- Briles DE, S Hollingshead, A Brooks-Walter, G Nabors, L Ferguson, M Schilling, S Gravenstein, P Braun, J King, A Swift. **The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection.** *Vaccine* 18:1707-1711, 2000.
- Hollingshead SK, DE Briles. ***Streptococcus pneumoniae*: new tools for an old pathogen.** *Current Opinions in Microbiology.* 4: 71-77. 2001.
- Briles DE, SK Hollingshead, GS Nabors, JC Paton, A Brooks-Walter. **The potential for using protein vaccines to protect against otitis media caused by *Streptococcus pneumoniae*.** *Vaccine.* 19:S87-S95. 2001.
- Briles DE, A Hakansson, H Roche, SK Hollingshead. New vaccines for non-serotype-dependent protection against pneumococcal disease. Third International Symposium on Antimicrobial Agents and Resistance. pp. 327-334. 2001.
- Paton JC, DE Briles. ***Streptococcus pneumoniae* vaccines.** In: R.W. Ellis and b.R. Brodeur (eds.). New Bacterial Vaccines. Landes Bioscience, Georgetown, Texas, USA. pp. 294-310. 2003.
- Briles DE, Paton, JC, Hollingshead SK. **Pneumococcal common proteins and other vaccine strategies.** Chapter for Levine's book. in Press 2003.
- Briles DE, SK Hollingshead, MJ Crain, B Ren, S Mirza, J Watt, J Johnston. **Pneumococcal proteins that may constitute the next generation vaccine for pneumococcal disease.** International Congress Series 1572:27-31. 2003.
- Briles DE, Paton, JC, Hollingshead SK. Pneumococcal common proteins and other vaccine strategies. In New Generation Vaccines, 3rd edition, Ed. MM. Levine, R Rappouli, M Liu, MF Good. Marcel Dekker, Inc. New York. p459-469. 2004.
- Swiatlo E, LS McDaniel, DE Briles. **Choline binding proteins.** in The Pneumococcus. Ed. EI Tuomanen. ASM Press pp 49-60. 2004.
- Briles DE, SK Hollingshead, B Ren, J. Watt. **Pneumococcal Proteins and their potential use in pneumococcal vaccines.** In 8th International Symposium on Recent Advances in Otitis Media. Edited by David Lim and Charles Bluestone, BC Decker, Hamilton, Ontario. pp 459-469. 2004.
- Briles DE, JC Paton, E Swiatlo, M. J. Crain. **Pneumococcal Vaccines.** In Gram Positive Pathogenes Book, Edited by VA Fischetti, RP Novick, JJ Ferretti, DA Portnoy, JI Rood. ASM Press. Washington D.C. 289-298. 2006.

- Briles DE, SK Hollingshead, I Jonsdottir. **Animal Models of Invasive Pneumococcal Disease**. In: Pneumococcal Vaccines: Impact of Conjugate Vaccine. Edited by Siber G, Klugman K, and Makela H. ASM Press. Washington D. C. pp 47-58. **2008**. Wright AK, DE Briles, DW Metzger, SB Gordon. **Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection**. Vaccine 26:4893-4903. **2008**
- Briles DE, M. Darrieux. **Novos alvos antigênicos para vacinas pneumocócicas**. In Proceedings of the Symposium on Immunobiologicals and Human Health, Bio-Manguinhos, 2006. In Press. 2008
- Briles DE, JC Paton, SK Hollingshead, JW Boslego. Pneumococcal common proteins and other vaccine strategies. In New Generation Vaccines, 4th edition, Chapter 46, Ed. MM Levine, G Dougan, MF Good, MA Liu, GJ Nabel, NP Nataro and R Rappouli. Marcel Dekker Inc. New York. Pp 482-488. 2010.
- Briles DE, E Miyaji, Y Fukuyama, DM Ferreira, and K Fujihashi. Elicitation of mucosal immunity by proteins of *Streptococcus pneumoniae*. Basel Karger, In *Advances in Adv. Otorhinolaryngol.* 72:25-27. 2011.
- Hotomi M, M Kono, SK Hollingshead, DE Briles, N Yamanaka. **Protection of pneumococcal infection by maternal immunization with pneumococcal surface protein A**. *Adv. Otorhinolaryngol.* 72: 121-125. **2011**.
- Tran TD, HY Kwon, EH Kim, KW Kim, DE Briles, S Pyo, DK Rhee. **Heat-shock protein ClpL/HSP100 increases penicillin tolerance in *Streptococcus pneumoniae***. *Adv. Otorhinolaryngol.* 72: 126-128. **2011**.
- Darrieux, M, C Goulart, DE Briles, LCC Leite, Current status and perspectives on protein-based pneumococcal vaccines, *Crit Rev Microbiol*, June 2013. In Press
- Fukuyama Y, Y Ikeda, J Ohori, G Sugita, K Aso, K Fujihashi, DE Briles, JR McGhee, K Fujihashi. A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly. *Immune Netw* 15: 9-15. 2015. PMID 43386268

LETTER to the EDITOR

- Swiatlo E, K Benton, DE Briles: **Pneumococcal vaccine response in human immunodeficiency virus-infected patients**. *J. Infect. Dis.* 173:777-778, 1996.